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                                           ABSTRACT 
Background 
Abnormalities of mineral bone disease have been consistently associated with adverse 
clinical outcomes in patients with chronic kidney disease (CKD). The consequences of these 
changes have also been shown to differ across races. However, in Africa the impact of 
derangements of CKD -mineral and bone disorder (CKD-MBD) on patients with CKD is 
largely unknown. In addition, studies from the USA have reported racial variations in 
markers of CKD and it remains unclear whether genetic factors may explain this discrepancy 
in the levels of biochemical markers of CKD-MBD across ethnic groups. Therefore, this 
study has been conducted to determine the existence of racial differences in the levels of 
fibroblast growth factor 23(FGF23) and traditional markers of mineral bone metabolism in a 
heterogeneous African CKD population, and to provide important insights into the pattern 
and genetic variability of CKD-MBD in sub-Saharan Africa. 
Methods 
This was a cross sectional multicenter study carried out from April 2015 to May 2016, 
involving two hundred and ninety three CKD patients from three renal units in Johannesburg, 
South Africa. The retrospective arm of this study involved two hundred and thirteen patients 
undergoing maintenance haemodialysis (MHD) from two dialysis centers in Johannesburg 
between January 2009 and March 2016. The first part of this study described the pattern of 
CKD-MBD in MHD patients using traditional markers of CKD-MBD. The second part of the 
study looked into the spectrum of CKD-MBD and racial variations in markers of CKD-MBD 
in pre dialysis and dialysis patients. This was followed by the genetic aspect of the study that 
examined the influence of vitamin D receptor polymorphisms on biochemical markers of 
mineral bone disorders. Lastly, the study also evaluated the association between markers of 
CKD-MBD and mortality in MHD patients. 
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Results 
The prevalence of hyperparathyroidism (iPTH>150 pg/mL), hyperphosphataemia, 
hypocalcaemia and 25-hydroxyvitamin D deficiency (<30 ng/mL) was 73.4%, 57.0%, 20.3% 
and 80.7 % respectively in our MHD patients. The combination of markers of bone turnover 
(iPTH>150 pg/mL and total alkaline phosphatase > 112 U/L) suggestive of high turnover 
bone disease, was present in 47.3 % of the study population. The odds ratios for developing 
secondary hyperparathyroidism with hypocalcaemia and hyperphosphataemia were 5.32 
(95% CI 1.10 - 25.9, P =0.03) and 3.06 (95 % CI 1.15 - 8.10, P =0.02) respectively. 
The 293 CKD patients (208 blacks, 85 whites) had an overall mean age of 51.1±13.6 years, 
and black patients were significantly younger than the white patients (48.4 ±.13.6 versus 
57.1±15.5 years; p<0.001). In comparison to whites, blacks had higher median iPTH (498 
[37-1084] versus 274[131-595] pg/ml; P=0.03), alkaline phosphatase (122[89-192] versus 
103[74-144] U/L; P=0.03) and mean 25- hydroxyvitamin D (26.8±12.7 versus 22.7 ±12.2 
ng/ml, P=0.01) levels, while their median FGF23 (100 [34-639] versus 233[80-1370] pg/ml; 
P=0.002) and  mean serum phosphate (1.3±0.5 versus 1.5±0.5, P =0.001)  levels were 
significantly lower. 
With the exception of vitamin D receptor (VDR) Taq I polymorphism, the distribution of the 
VDR polymorphisms differs significantly between blacks and whites. In hemodialysis 
patients, the BsmI Bb genotype was significantly associated with moderate secondary 
hyperparathyroidism (OR, 3.88; 95 CI 1.13-13.25, P=0.03)   and severe hyperparathyroidism 
(OR, 2.54; 95 CI 1.08-5.96, P=0.03).  
Patients with high total alkaline phosphatase (TAP) had significantly higher risk of death 
compared to patients with TAP <112 U/L (hazard ratio, 2.50; 95% CI 1.24–5.01, P = 0.01). 
Similarly, serum calcium >2.75 mmol/L was associated with increased risk of death 
compared to patients within levels of 2.10–2.37 mmol/L (HR 6.34, 95% CI 1.40–28.76; P = 
0.02). The HR for death in white patients compared to black patients was 6.88; 95% CI 1.82–
25.88; P = 0.004. 
Conclusions 
Secondary hyperparathyroidism and 25–hydroxyvitamin D deficiency were common in our 
haemodialysis patients. The study also highlighted the existence of racial differences in the 
circulating markers of mineral bone disorders in our African CKD population. In addition, 
the study showed that both moderate and severe secondary hyperparathyroidism are predicted 
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by the BsmI Bb genotype, and the over expression of this genotype in black patients may 
partly explain the ethnic variations in the severity of secondary hyperparathyroidism in the 
CKD population. High levels of serum alkaline phosphatase, hypercalcaemia, and white race 
are associated with increased risk of death in MHD patients. 
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                                                PREFACE 
Despite the existence of regional and global guidelines to curtail the adverse clinical 
outcomes associated with CKD-MBD, the majority of CKD patients are still affected by the 
consequences of abnormalities of CKD-MBD. In Africa, the spectrum and burden of CKD-
MBD is largely unknown. In addition, studies from the USA have shown racial variations in 
markers of CKD-MBD, and survival advantage associated with black patients on 
haemodialysis. However, due to variations in practice pattern, geographic location, and 
genetic factors between Africa and the USA, it remains unclear if data obtained from the 
USA CKD population could be extrapolated to African CKD patients.  Furthermore, in 2013 
the KDIGO working group highlighted the existence of large gaps in knowledge in the field 
of CKD-MBD and thus recommended the need for further studies to assist in updating the 
2009 KDIGO clinical practice guidelines on the diagnosis and treatment of CKD-MBD. 
Therefore, based on the above aforementioned reasons, this study was undertaken to 
determine the spectrum and burden of CKD-MBD in South African patients with CKD, the 
existence of ethnic variations in markers of CKD-MBD in a heterogeneous African CKD 
population, and the influence of VDR polymorphisms on secondary hyperparathyroidism. 
Information obtained from this study will assist us in better understanding of factors 
associated with mortality and with improving patients’ outcomes. It will also provide an 
insight on candidate genes associated with secondary hyperparathyroidism and likely provide 
an additional target for the treatment of secondary hyperparathyroidism. 
This thesis is presented in an integrated format consisting of seven chapters:  
Chapter 1: Literature review 
Chapter 2: Overall Methodology 
Chapter 3: Manuscript on biochemical markers of mineral bone disorder in South African 
patients on maintenance haemodialysis. (Published in the African Health Sciences Journal 
July, 2017).  
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Chapter 4: Manuscript on high serum alkaline phosphatase, hypercalcaemia, race and 
mortality in South African maintenance haemodialysis patients. (Published in the 
International Journal of Nephrology, 12
th 
January, 2017) 
Chapter 5: Manuscript on racial variations in the markers of mineral bone disorders in 
chronic kidney disease patients in South Africa. Undergoing peer review by the Kidney 
International Reports. 
Chapter 6: Manuscript on influence of vitamin D receptor polymorphisms on biochemical 
markers of mineral bone disorders in South African patients with chronic kidney disease. 
Accepted for publication in BMC Nephrology. October, 2017. 
Chapter 7: Consists of an integrated summary of the study findings, limitations, 
recommendations and conclusions 
Candidate’s contributions 
I was responsible for the conceptualization of this project, writing up the protocol and 
collection of data. All the manuscripts were drafted by me. I conducted all the statistical 
analysis. The laboratory work was carried out by me under the supervision of my laboratory 
collaborators.  
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                           CHAPTER 1: LITERATURE REVIEW 
1.1 Introduction 
Chronic kidney disease (CKD) is a worldwide health problem affecting 5–10% of the world’s 
population (1, 2) and the majority of these patients are at an increased risk of developing 
disturbances of bone and mineral metabolism. These disturbances lead to a constellation of 
bone lesions which was previously referred to as renal osteodystrophy (ROD), with affected 
patients manifesting with symptoms such as bone pain, muscle tendon rupture, pruritus and 
high incidence of fractures (3, 4). Subsequently, evidence has shown that patients with ROD 
are also predisposed to cardiovascular calcification with associated high morbidity and 
mortality rates (5, 6). Unfortunately, the term ROD does not encompass this important extra 
skeletal manifestation. Therefore, to address these drawbacks and accommodate the extra 
skeletal manifestations, the Kidney Disease-Improving Global Outcomes (KDIGO) 
Foundation initiated a controversies conference with the aim of providing a globally 
acceptable definition and classification system for renal osteodystrophy. The KDIGO work 
group recommended a broader term, CKD-mineral and bone disorder  (CKD-MBD) for a 
systemic disorder of mineral and bone metabolism due to CKD and that the term renal 
osteodystrophy should exclusively be used to describe disorders in bone morphology 
associated with CKD (6). However, in clinical settings, a bone biopsy is less frequently 
utilized because it is an invasive and cumbersome procedure and requires highly skilled 
personnel to interpret the obtained tissue samples. For these reasons, clinicians largely 
depend on trends in the levels of parathyroid hormone in conjunction with levels of serum 
phosphate, calcium and alkaline phosphatase as markers of bone turnover which are used to 
guide the treatment of mineral bone disorder (4). However, the practice of utilizing one 
biomarker to predict the complex dynamic bone remodelling process has been questioned (6, 
7). Therefore, one of the objectives of this study is to further assess other biochemical 
markers of bone turnover (FGF23, total alkaline phosphatase) and correlate them with 
parathyroid hormone (PTH).  
Furthermore, several studies have shown race to be an important factor that may influence 
PTH, serum phosphate and vitamin D levels (8-10). These studies showed that compared 
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with whites, blacks have higher PTH and lower 25-hydroxyvitamin D [25 (OH) D] levels. 
These comparative studies were largely carried out between Caucasians and Black Americans 
and little is known about the association in African CKD patients. In addition, the impact of 
these biochemical abnormalities have been shown to differ across race and thus the need for 
race-specific target values for these markers of mineral bone disorder (11). This study also 
seeks to examine the impact of these markers in a heterogeneous African CKD population. 
Although the mechanism behind racial variation in the levels of biochemical markers of 
chronic kidney disease mineral and bone disorders (CKD-MBD) remains unclear, it may be 
explained partly by genetic factors.  Hence, one of the objectives of this study was to examine 
the influence of VDR polymorphisms on secondary hyperparathyroidism and its association 
with vitamin D levels in black and white South African study participants. 
1.2 Historical perspectives 
The association between kidney diseases and bone abnormalities dates back to 1883, when 
Lucas suggested the term “ renal rickets”  in patients with albuminuria and bone deformities 
(12). In 1930, Bauer et al (13) established an association between bone lesions (osteitis 
fibrosacystica) and the parathyroid gland following a review of 88 patients with endocrine 
bone disorders. Seven years later, Albright and colleagues postulated that CKD patients with 
phosphate retention and low levels of calcium are prone to parathyroid gland hyperplasia and 
renal osteitis fibrosa. Subsequently, in 1940s, the term renal osteodystrophy was coined and 
used interchangeably with renal rickets (14). 
The emergence of the “trade off hypothesis” by Bricker and Slatopolsky (15, 16) provided an 
insight into the pathogenesis of renal osteodystrophy. The theory states that progressive 
nephron loss in CKD patients leads to a number of compensatory mechanisms such as 
elevated PTH in response to retained phosphate.  
In the 1960s and 1970s, the two predominant forms of renal osteodystrophy in patients with 
end stage kidney disease (ESKD) were osteitis fibrosa and mixed uraemic osteodystrophy 
with a minority of patients presenting with osteomalacia prior to dialysis (17). However, 
osteomalacia became a major problem following initiation of dialysis secondary to aluminum 
intoxication in some centers; the two most affected dialysis centers (Ottawa and Newcastle) 
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had high concentrations of aluminum and fluoride in their tap water. This entity of renal 
osteodystrophy (osteomalacia) was characterized by microcytic anaemia and encephalopathy 
(18).  However, adynamic  bone disease was not only peculiar to aluminum contamination of 
tap water used for dialysis but also associated with the use of large amounts of aluminum  
containing phosphate binders and active vitamin D therapy (19). Subsequently, there was a 
rapid decline in the occurrence of this disease entity with improvement in water purification 
systems and reduced prescription of aluminum-containing phosphate binders. 
1. 3 Definitions and Guidelines 
  1.3.1 Definitions 
In 2003, the National Kidney Foundation proposed that renal osteodystrophy  should be 
defined as a  constellation of bone disorders present or exacerbated by CKD that lead to bone 
fragility and fractures, abnormal mineral metabolism, and extra skeletal manifestations (20). 
Despite incorporating a triad of abnormal mineral metabolism, skeletal and extra skeletal 
manifestations this definition failed to be acceptable globally. Therefore, to ensure a widely 
acceptable definition, the second KDIGO controversies conference in 2005 came up with a 
broader term CKD-MBD. The conference participants agreed that CKD-MBD should be 
defined “as a systemic disorder of mineral and bone metabolism due to CKD manifested by 
either one or a combination of the following: (i) abnormalities of calcium, phosphorus, 
parathyroid hormone (PTH), or vitamin D metabolism; (ii) abnormalities in bone turnover, 
mineralization, volume, linear growth, or strength; or (iii) vascular or other soft tissue 
calcification” (6). This internationally acceptable definition has led to ease of valid 
comparison of studies in the field of CKD-MBD. 
1.3.2 Guidelines 
In an ongoing effort to reduce the adverse clinical events associated with CKD-MBD, several 
global and regional guidelines were proposed to assist clinicians in the management of 
patients with CKD-MBD. These guidelines provided recommended target reference values 
for intact PTH, alkaline phosphatase and serum calcium. However, comparison of these 
guidelines has shown lack of harmonization with the existence of relevant clinical differences 
in the target values (21). For example in 2003, the Kidney Disease Outcomes Quality 
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Initiative (K/DOQI) clinical practice guidelines recommended  maintaining  serum phosphate 
between 3.5 and 5.5mg/dL (1.13–1.78 mmol/L) for CKD stage 5D, serum parathyroid 
hormone (PTH) between 150 and 300 pg/mL(16.5–33.0 pmol/L) and corrected serum 
calcium in the range of  8.4 and 9.5 mg/dL (2.10–2.37 mmol/L) (20), while in 2009, the 
KDIGO clinical practice guidelines recommended  maintaining  serum  calcium and 
phosphate   within the normal range and plasma PTH in the range of two to nine times the 
upper normal limit of the assay (22). One of the major drawbacks of the KDIGO guideline, 
which has drawn criticism, is the vagueness of some of the non-numerically defined 
recommendations. Despite these drawbacks, it is still preferred to the narrow target levels of 
calcium, PTH and phosphorous, as recommended by the 2003 KDOQI guidelines. 
Table 1. 1: Recommended guidelines by different professional groups 
     Group Year Recommended levels 
Corrected 
calcium (mg/dl) 
Phosphorous 
(mg/dl) 
PTH (pg/ml) 
UK Renal 
Association (23) 
2002 8.8-10.4 < 5.6 < 4× upper normal 
range 
K/DOQI  (20) 2003 8.4-9.5 3.5-5.5 150-300 
Canadian Society of 
Nephrology  (24) 
2006 Within normal 
range 
Within normal 
range 
100-500 
Japanese Society for 
Dialysis Therapy  
(25)  
2008 8.4-10.0 3.5-6.0 60-240 
KDIGO (22) 2009 Within normal 
range 
Within normal 
range 
2- 9× upper limit of 
normal 
KDIGO= Kidney Disease -Improving Global Outcomes, K/DOQI= Kidney Disease Outcomes Quality Initiative, UK= United Kingdom, 
PTH= Parathyroid hormone. 
 
1.3 Pathogenesis of CKD-MBD 
Classically, prior to the discovery of Fibroblast Growth Factor 23 (FGF23), phosphate 
retention due to a decline in renal function had been considered as the main trigger of 
secondary hyperparathyroidism (26). The retained phosphate leads to a triad  of 
hyperphosphataemia, low 1,25(OH)2D3 and hypocalcaemia which are well-known stimuli 
for  PTH secretion that in turn enhances phosphate excretion and development of  secondary 
hyperparathyroidism in advanced CKD. However, what mitigates this process in the early 
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stages of CKD continued to be a point of discussion. Some authors have observed that 
calcitriol deficiency occurred earlier than hyperphosphatemia and hypocalcemia suggesting 
that it may be the main initiator of secondary hyperparathyroidism. Therefore, the 
pathophysiology of secondary hyperparathyroidism is a complex process that involves an 
interaction between several factors. In the classic hypothesis, the trade-off of PTH for 
normalization of calcium and phosphate levels is the development of secondary 
hyperparathyroidism (15, 27). The role of phosphate in the pathogenesis of secondary 
hyperparathyroidism was further supported by studies that demonstrated an association 
between high phosphate diets and parathyroid hyperplasia (28, 29). However, the 
pathophysiology of secondary hyperparathyroidism has evolved with new discoveries (4). 
For example, the emergence of FGF23 has revolutionized the understanding of the 
mechanisms underlying the development of secondary hyperparathyroidism, leading to an 
updated trade-off hypothesis.  Plasma FGF23 levels become elevated with progressively 
worsening renal function, likely to occur before observed changes in the levels of phosphate 
and PTH (30). 
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Figure 1. 1: Classic versus updated hypothesis for the evolution of CKD MBD ( 27)  
 
1.4.1 Role of FGF23 in the pathogenesis of secondary hyperparathyroidism 
Fibroblast growth factor 23 (FGF23) is derived from osteocytes and plays a vital role in 
vitamin D and phosphate metabolism. It requires Klotho (a transmembrane protein) to enable 
it to bind to the FGF receptor (FGFR) in classic target organs such as kidneys and parathyroid 
glands (31). Klotho is a transmembrane protein that confers tissue specificity to FGF23. The 
importance of this co-receptor was demonstrated in klotho null mice showing a phenotype 
similar to that of FGF23 null mice, with features of premature aging, vascular calcification, 
altered calcium/phosphate metabolism with hyperphosphataemia, and shortened lifespan (32, 
33).  Fibroblast growth factor 23 enhances phosphate excretion in the proximal renal tubule 
by decreasing the expression of luminal sodium-dependent phosphate transporters, and may 
also decrease intestinal phosphate absorption by inhibiting NaPi cotransporter activity (34).  
In addition, it reduces synthesis of 1, 25-dihydroxyvitamin D [1, 25(OH) 2D3] by down-
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regulating the activity of 1α-hydroxylase and accentuating the activity of 24-hydroxylase (35, 
36). In early stages of CKD, high levels of FGF23 attenuate hyperphosphataemia at the 
expense of 1, 25(OH) 2 vitamin D suppression, thus initiating the development of secondary 
hyperparathyroidism (36). The decrease in serum 1, 25 (OH) 2D3 leads to decreased intestinal 
calcium absorption. The triad of low levels of calcium, calcitriol and hyperphosphataemia 
further enhances excessive PTH secretion. This excess PTH leads to mobilization of calcium 
from the bone and osteitis fibrosa. Other consequences of progressive worsening of kidney 
function include hypo responsiveness of the vitamin D receptor (VDR) on the parathyroid 
gland with further enhancement of PTH production and reduced expression of the calcium 
sensing receptor on the parathyroid gland leading to parathyroid gland hyperplasia. In some 
subset of patients, the parathyroid gland undergoes hypertrophy and becomes autonomous 
(37).   
1.5   Diagnosis of CKD-MBD 
In 1983, Sherald et al. (38) proposed a classification for renal oesteodystrophy based on bone 
histomorphometry findings namely: high turnover disease, low turnover and mixed uraemic 
osteodystrophy. The emphasis on this classification was on bone turnover; however, since 
bone biopsy is not routinely used for monitoring patients there is a need for reliable 
biomarkers for assessing and monitoring patients with CKD-MBD.  Therefore, the KDIGO 
guidelines recommended the use of serum PTH in conjunction with total or bone specific 
alkaline phosphatase (b-ALP) since high or low levels of these markers correlate with 
underlying bone turnover. In addition, due to the dynamic nature and complexity of bone 
homeostasis, it is difficult to rely on one biochemical marker as a surrogate test of bone 
formation (39). Therefore, utilizing both PTH and b-ALP as recommended by the KDIGO 
group may be necessary. Furthermore, in an attempt to address the diagnostic utility of 
various biochemical markers of mineral bone disorders, the KDIGO group conducted one of 
the largest bone biopsy studies involving 492 dialysis patients. In their multivariate analysis, 
both intact PTH and whole PTH were found to remain significantly predictive in 
differentiating high from non-high bone turnover. In addition to PTH, they also assessed the 
additive value of bone- specific alkaline phosphatase and the amino – terminal propeptide of 
type 1 procollagen (PINP) in providing diagnostic accuracy. Surprisingly, the inclusion of 
specific b-ALP level added only non-statistically significant value to PTH while PINP did not 
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(40). However, due to limited serum samples they could not assess the diagnostic utility of 
FGF23, 25 (OH) D and other newer biomarkers of CKD-MBD. 
1.5.1 Parathyroid hormone 
The parathyroid gland plays a vital role in the regulation of mineral bone homeostasis 
through a complex interaction with the bone and kidney. Alterations in extracellular levels of 
calcium ion are perceived by the parathyroid calcium sensing receptors (CaSRs) which 
further regulate the production and secretion of PTH (41). Parathyroid hormone exerts its 
effects on the bone to enhance mobilization of calcium and phosphate, while on the kidneys it 
inhibits urinary excretion of calcium and phosphate reabsorption. It also enhances the 
synthesis of 1, 25(OH) 2D3.  The first generation PTH assays were the radioimmunoassays 
(RIAs) that utilized an antibody to locate an epitope in the c-terminal or mid portions of the 
PTH molecule. The first generation assays were later found to be associated with some 
drawbacks such as cross reactivity with other fragments of PTH (mid and carboxyl terminal). 
These fragments are produced by the liver and excreted by the kidneys. Therefore, as a result 
of cross reactivity, levels of PTH measured in CKD patients by these assays will be markedly 
elevated (42).  Subsequently, in the 1980s, the two site immunoradiometric assays were 
launched to address the inadequacies associated with the first generation assays (43). The 
second generation assay which is being used in our study specifically measures the full length 
PTH (Intact PTH). Although, more recently, it was believed that the second generation assays 
may also recognize other fragments such as PTH (7-84) (44), it still remains the most widely 
used assay. The third generation assays which are now believed to be specific for PTH (1-84) 
are also available (45). However, the improved diagnostic value of the third generation as 
compared to second generation assays has not been established (46). In 2001, Monier et al. 
(47) assessed whether the use of the plasma PTH (1-84)/C-PTH fragment ratio could predict 
bone turnover better than individual PTH levels measured with second or third generation 
assays. Their results showed that the  PTH-(1-84)/C-PTH fragment ratio was the best 
predictor of bone turnover, with  a ratio> 1 predicting  high or normal bone turnover 
(sensitivity 100%),  while a ratio <1 indicated a high probability (sensitivity 87.5%) of  low 
bone turnover.  However, subsequent studies did not find any advantage in assessment of 
bone turnover with this ratio compared to a single value of PTH. Therefore, the KDIGO 
group is of the opinion that both second and third generation assays are comparable, with not 
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enough evidence to recommend switching to the third generation assay. Similarly, the use of 
both assays to arrive at a ratio will lead to a considerable increase in costs of evaluating 
CKD-MBD.  Despite the limitations associated with PTH measurement, it still remains the 
recommended marker for monitoring CKD-MBD. The choice of PTH as a marker for 
monitoring secondary hyperparathyroidism has been supported by studies that correlated 
elevated levels of these hormones with poor clinical outcomes. The US Renal Data System 
revealed reduction in fracture risk by 32 % post parathyroidectomy after adjusting for 
confounding variables (48). In another study, independent of age and diabetes status, elevated 
levels of PTH were associated with a history of heart failure and myocardial infarction (49).  
Additionally, in a large randomized trial, decreased levels of PTH with paricalcitol therapy 
was significantly associated with decreased cardiovascular hospitalization (50). Furthermore, 
bone remodeling is a dynamic process with an average remodeling cycle of 3-6 months for an 
area of bone. Therefore, the use of multiple bone biopsies as a gold standard for diagnosing 
and monitoring renal osteodystrophy is impracticable. In clinical settings, an ideal biomarker 
for monitoring the management of CKD-MBD should be noninvasive and can be repeatedly 
measured 
1.6   Classification of markers of bone turnover 
The complex and dynamic processes of bone remodeling are under the influence of 
osteoclasts (bone resorption), osteoblasts (bone formation) and osteocytes (bone 
maintenance) (51).  In healthy individuals, these complex interactions ensure that the amount 
of bone removed is replaced with newly formed bone (51). In CKD patients, there is 
dysregulation of this balance which is reflected by abnormal levels of markers of bone 
turnover. These markers can broadly be categorized into markers of bone formation and bone 
resorption as shown in Table 1.2. 
1.6.1 Total alkaline phosphatase (TAP) 
Prior to the availability of commercial intact parathyroid hormone (PTH) assays, serum total 
alkaline phosphatase (TAP) measurements were used as one of the surrogate markers of high 
bone turnover that was utilized in the management of CKD-MBD (52). Alkaline 
phosphatases are membrane-bound tetrameric enzymes that extract phosphate from proteins 
and nucleotides at alkaline PH (4, 53). TAP is produced by various organs such as intestine, 
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liver, kidney, and bone. However, in healthy adults, the TAP activity in serum is derived 
mainly from the bone and the liver (51). They are involved in osteoid formation and 
mineralization. Although not as specific as bone specific alkaline phosphatase, serum TAP is 
the most widely utilized marker of bone formation because it is readily available and 
inexpensive. In addition, studies have reported a good correlation between bone specific 
alkaline phosphatase and TAP (51). 
1.6.2 Specific bone alkaline phosphatase (b-ALP) 
Specific b-ALP originates from osteoblasts and is involved in osteoid formation and 
mineralization. Studies have revealed a significant correlation between bone formation rate 
and bone specific alkaline phosphatase (54, 55). Studies relating to its superiority to PTH in 
identifying low versus high bone turnover have been inconsistent. For example, Couttenye  et 
al. (56) showed that bone specific b-ALP has a better positive predictive value than PTH in 
identifying adynamic bone disease in haemodialysis patients, while Lehmann et al. (57) 
demonstrated that the  predictive ability  for high versus low bone turnover status was similar 
for TAP, b-ALP,  tartrate resistant acid phosphatase (TRAP 5b) and parathyroid hormone in 
CKD Stage 5 patients.  
1.6.3 Osteocalcin (OC)   
Osteocalcin (OC) which is also called bone-Gla protein, is exclusively produced by 
osteoblasts, odontoblasts and chondrocytes and thus considered a marker osteoblast function 
(51). A histomorphometry study has reported a good correlation between serum levels of OC 
and  bone formation rate (58). Osteocalcin is unstable in serum and rapidly degrades into OC 
fragments and intact peptide. The various assays used to measure serum OC have been shown 
to detect fragments of various sizes, thus limiting their application in clinical practice (51). 
1.6.4 Procollagen Type I Propeptides 
The procollagen type I propeptides are synthesized from collagen type I, which is the 
predominant form of collagen found in bone (51). Type I collagen could also be found in 
other tissues such as skin, cornea, blood vessels, tendons and cartilages. This collagen is 
produced mainly by osteoblasts in the form of a procollagen molecule during bone formation. 
This procollagen molecule consists of short terminal peptides namely the carboxy (C-) 
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terminal propeptide (PICP) and the amino (N-) terminal propeptide (PINP (59). In 2011, the 
International Osteoporosis Foundation (IOF) and the International Federation of Clinical 
Chemistry and Laboratory Medicine (IFCC) made a recommendation that a marker of bone 
formation (serum procollagen type I N propeptide, s-PINP) and a marker of bone resorption 
(serum C-terminal telopeptide of type I collagen, s-CTX) should be used as reference 
analytes for bone turnover markers in clinical studies, particularly for monitoring 
osteoporosis (59). However, it is noteworthy that the KDIGO guidelines did not recommend 
routine measurements of markers of collagen synthesis such as CTX in patients with CKD 
stages 3-5D. The reason for this recommendation was based on the evidence that the levels of 
these markers did not appear to be more superior at predicting bone histology than serum 
PTH or specific bone alkaline phosphatase (22).  
1.6.5 Tartrate – resistant acid phosphatase (TRAP-5B)  
This is another marker of bone resorption which is produced by osteoclasts (60). Compared 
to PTH and PINP, TRAP- 5B has been shown to correlate more strongly with histological 
indices of osteoclasts, and found to be very stable and not affected by kidney function or 
fasting status of the patients (61, 62).  
Other markers of bone turnover are summarized in Table 1.2. 
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Table 1. 2: Markers of bone turnover (51) 
Marker Tissue of origin Specimen Comments 
Bone formation    
Specific bone alkaline 
phosphatase (b-ALP) 
Bone Serum Originate from osteoblasts 
Osteocalcin (OC) Bone, Platelets Serum Predominantly from osteoblasts 
C-terminal propeptide 
of type I procollagen 
(PICP) 
Bone, soft tissue, 
skin 
Serum  Arises from proliferating osteoblasts and 
fibroblasts 
N-terminal propeptide 
of type I procollagen 
(PINP) 
Bone, soft tissue, 
skin 
Serum Arises from  proliferating osteoblast and 
fibroblasts 
Bone resorption    
Hydroxyproline 
 
Bone, cartilage, 
soft tissue, skin 
Urine Present in both the newly synthesized and 
the mature collagen.  
 
Hydroxylysine 
glycosides 
Bone, soft tissue, 
skin, serum & 
complement  
Urine 
serum 
Hydroxylysine in collagen is glycosylated 
to varying degrees, depending on tissue 
type 
Carboxyterminal 
crosslinked 
telopeptide of type I 
collagen (CTX-I) 
All tissues 
containing type I 
collagen 
Urine (a-/ 
s) Serum (s 
only) 
Collagen type I, predominantly from the 
bone.  Isomerisation of aspartyl to s-
aspartyl occurs with ageing of collagen 
molecule. 
Aminoterminal 
crosslinked 
telopeptide of type I 
collagen (NTX-I) 
All tissues 
containing type I 
collagen 
Urine 
Serum 
Collagen type I, predominantly from the 
bone. 
Bone Sialoprotein 
(BSP) 
Bone, Dentin, 
hypertrophic 
cartilage 
Serum Synthesized by osteoblasts and osteoclastic 
cells. 
Tartrate-resistant acid 
phosphatase 
Bone Blood Plasma 
Serum 
Six isoenzymes are present in the human 
tissues and b and 5b predominates in the 
bone (Osteoclasts). 
Cathepsins (K,L)  Osteoclasts  
Macrophage, 
Osteoclasts 
 
Plasma, 
Serum 
Cathepsin K plays an essential role in 
osteoclast-mediated bone matrix  
 
Dual-energy X-ray absorptiometry (DXA) is a non invasive radiological technique used in  
the assessment of mineral bone density, although largely utilized in predicting bone fracture 
in healthy population,  the findings in  evaluating risk fracture using DXA in patients with 
CKD 3-5D  have been inconsistent and limited by cross sectional study design (63). 
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Furthermore, the use DXA to identify osteoporosis in the healthy population which is 
characterized by low bone mineral density may be inappropriate in patients with advanced 
CKD, since abnormal markers of CKD-MBD will lead to poor bone quality even in the 
setting of normal mineral or high mineral bone content (22, 63). Thus the 2009 KIDIGO 
guidelines made no recommendations for the routine use of DXA in patients with CKD 3-5D 
(22).  However, four recent prospective studies consistently reported that hip BMD predicted 
bone fractures in CKD patients and based on these findings, the recently 2017 updated 
guidelines recommended assessment of BMD using DXA in high risk patients (64). 
1.7 Prevalence of secondary hyperparathyroidism 
The pattern of CKD-MBD has evolved over time due to various factors such as change in 
practice patterns, underlying aetiology of CKD and duration on dialysis (65). For example, in 
1996, Coen et al. (66) reported the following biopsy findings in 76 Italian CKD patients not 
on bone-related medications:  adyanamic bone disease in 9 patients, mixed osteodystrophy in 
26, advanced mixed osteodystrophy in 22, predominant hyperparathyroidism in 2, 
predominant osteomalacia in 7 and normal features in 10. Two other studies were 
contradictory in relation to the prevalence of adyanamic bone disease in predialysis CKD 
patients.  Dhal et al. (67) reported that osteomalacia was rare in predialysis CKD, while Mora 
Palma et al. (68) reported that osteomalacia was a common finding in predialysis CKD 
patients with chronic tubulointerstitial nephritis. However, comparison of the prevalence of 
adyanamic bone disease across studies is difficult due to a lack of standardized definition. 
In a review of 1209 bone biopsies for patients on dialysis in several Latin American 
countries, Jorgetti et al. (69) reported  that osteomalacia and mixed forms of bone disease due 
to aluminum deposition were more prevalent in Brazil, Argentina and Uruguay, while in 
Portugal and Spain, high bone turnover due to  secondary hyperparathyroidism were the 
predominant forms. 
Subsequently in the late 1990s to date, most studies on the spectrum of CKD-MBD were 
based on biochemical parameters of bone turnover, likely due to ease of measurement, 
minimally invasive and significant association between levels of these markers and adverse 
clinical outcomes (70). In addition, the availability of global guidelines has allowed 
comparisons of biochemical parameters across studies.  
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Data from the Dialysis Outcomes and Practice Patterns (DOPPS) study revealed a wide 
variation in the abnormal markers of bone disease across different countries. Based on 
KDOQI recommended PTH values (150 to 300pg/ml), the proportion of patients with PTH > 
300 pg/ml were 30.3 % for the United States, 26.9 % for European countries, and 19.0 % for 
Japan. The factors positively associated with hyperparathyroidism (>300 pg/dL) were black 
race, duration of ESKD and vitamin D therapy (71). 
 In the CORES study involving six Latin American countries, the proportion of patients with 
PTH levels above 300 pg/ml was 30.9 %; 26.2 % were within the KDOQI recommended 
targets, and 42.8 % were below 150 pg/ml (72). 
Studies from India have reported a high prevalence of secondary hyperparathyroidism in 
haemodialysis populations. In a cross sectional study involving 150 predialysis and dialysis 
patients, high prevalence of secondary hyperparathyroidism was reported in both CKD stage 
4 and CKD stage 5D (84.62% versus 88.29%) (73). The use of a PTH cut off value of 69 
pg/mL for the advanced stages of CKD might have contributed to the high prevalence. 
However, in another study from India,  a similar trend was reported with higher cut off 
values, 50 (72%) patients had PTH levels greater than twice the upper range of normal and 45 
(61%) patients had PTH >300 pg/ml (74).  
In Africa, few studies have described the pattern of CKD-MBD based on biochemical 
parameters. 
In a cross sectional study involving 103 MHD patients from Libya, patients were categorized 
according to PTH into three categories: hyperparathyroid bone disease (iPTH> 450 pg/ml), 
adynamic bone disease (iPTH< 60 pg/ml), normal bone (iPTH 60 to 450 pg/ml). Based on 
this categorization, 29 of the patients (28.1%) had biochemical evidence of hyperparathyroid 
bone disease (iPTH>450 pg/ml) and 28 patients (27%) had low turnover adynamic bone 
disease (iPTH<60 pg/ml) and overall prevalence of ROD was 55.3% (75).  Another study 
from Senegal reported a very high prevalence of secondary hyperparathyroidism in 57 of the 
118 patients (76). These studies were limited by smaller sample sizes and non-availability of 
data on vitamin D status. In addition, the exact cut off value of PTH used in the Senegal study 
was not stated.  The present study aimed to improve on these limitations by enrolling larger 
number of patients, assessing vitamin D and FGF23 levels.  
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Patterns of CKD-MBD in Diabetes Mellitus 
Diabetes mellitus (DM) has been shown to alter bone modelling by modulating the functions 
of both osteoblasts and osteoclasts (77, 78). Type 2 Diabetes mellitus is associated with 
decreased bone remodeling. Type 2 diabetic patients were reported to have 20-50% lower 
PTH levels than the controls, despite reduced GFR, which is indicative of reduced PTH 
secretion in diabetic patients (79). Similarly, other bone markers of bone turnover such as 
osteocalcin, PINP and β-C-terminal telopeptide of type collagen (β-CTX) were lower in 
patients with type 2 DM as compared to non-diabetic patients (80). These findings were 
further supported by studies that utilized bone biopsy that reported low bone formation with 
reduced mineralization in diabetic patients (81, 82).The mechanism behind this low bone 
formation is largely attributed to increased accumulation of advanced glycation end products 
(AGEs) in bone matrix (83). The accumulated AGES in the bone matrix ultimately distort the 
activity of both osteoclasts and osteoblasts leading low bone formation in this group of 
patients. 
1.8 Clinical impact of CKD-MBD 
Several observational studies have shown an association between deranged markers of MBD 
and poor clinical outcomes in both predialysis and dialysis patients. For example, elevated 
levels of phosphate, calcium and PTH have been shown to be associated with cardiovascular-
specific mortality in patients with CKD. In a large, prospective, multicenter, cohort study 
(Netherlands Cooperative Study on the Adequacy of Dialysis) involving 1,629 haemodialysis 
and  peritoneal dialysis patients, a significant increase in hazard ratio (HR) of 1.57 (1.07–
2.30) in patients with the highest quartile of phosphate using both baseline and time-
dependent values was reported (84). Similarly, Block et al. (85) reported  an increased risk  of 
death with  increasing levels of phosphate, RR  1.07, 1.25, 1.43, 1.67, and 2.02 for serum 
phosphorus levels of 5.0 to 6.0, 6.0 to 7.0, 7.0 to 8.0, 8.0 to 9.0, and >9.0 mg/dL respectively 
in 40,538 patients on maintenance haemodialysis. The consistent association of 
hyperphosphataemia with increased mortality has been linked to its direct calcifying effect on 
coronary vessels and cardiac valves. 
Studies relating to PTH have shown a “U” shaped association with increased risk of death at 
extreme values of PTH.  The highest value of PTH that is associated with increased risk of 
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death varies across studies from >400 pg/mL (86) to >500 pg/mL (87) and >600 pg/mL (85). 
On the lower end of PTH, some studies have associated PTH below the K/DOQI 
recommended lower threshold (<150 pg/mL) with increased death risk (86, 88). 
Despite the differences in the cut-off points utilized by various studies, hypercalcaemia has 
been consistently associated with increased risk of mortality in MHD patients (89, 90).  In the 
three phases of the dialysis outcomes and practice patterns study (DOPPSI, II and III) with 
25,588 HD patients, calcium levels greater than 10.0 mg/dL (>2.5 mmol/L) were significantly 
associated with greater risk of all cause and cardiovascular mortality in both baseline and 
time dependent  models (90). The reasons for this consistent association could be linked to 
acceleration of arterial calcification by hypercalcaemia (91, 92). 
 A triad of high calcium, elevated phosphate levels and high or low PTH levels was 
associated with increased mortality in MHD patients (93). Alkaline phosphatase which is one 
of the markers of high bone turnover was recommended to be measured annually by the 
KDIGO. This relatively cheap diagnostic test has been consistently associated with increased 
mortality in both predialysis and dialysis populations (94-96).  For example, a USA 
multicenter observational study of haemodialysis patients reported that higher levels of 
alkaline phosphatase were associated with increased risk of hospitalization and death (94). 
Bhedu et al. (96) reported a similar association with higher levels of alkaline phosphatase in 
patients with CKD stages 3 and 4. Their findings suggested that independent of confounding 
variables such as liver function, serum phosphate and calcium, serum alkaline phosphatase 
was associated with increased risk of death in predialysis CKD patients. The role of high 
levels of alkaline phosphatase in the pathogenesis of vascular calcification was supported by 
a longitudinal study involving 134 stage 4 and 5 CKD patients (88). This 2 year prospective 
study revealed that higher levels of serum alkaline phosphatase were significantly associated 
with progressive vascular calcification (97). This relationship was independent of levels of 
serum fetuin –A, calcium, C – reactive protein and PTH. 
1.8.1 FGF23 and CKD progression 
Studies have shown a strong correlation between serum FGF23 levels and eGFR.  As renal 
function declines FGF23 levels increase. In end-stage renal disease, FGF23 levels can be up 
to 1000-fold above the normal range, likely due to retained phosphate or decreased renal 
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clearance (98). In a prospective study involving 177 non-diabetic patients with CKD stages 1-
5, with a median follow up period of 53 months, both serum intact FGF23 (iFGF23) and c-
terminal FGF23 levels (cFGF) above optimal cut-off levels predicted a doubling of serum 
creatinine and/or the need for renal replacement therapy, independent of eGFR, proteinuria, 
and other indices of mineral metabolism, such as calcium, phosphate and parathyroid 
hormone (99). 
Similarly, in a Brazilian prospective study comprising type 2 diabetes mellitus patients with 
macroalbuminuric nephropathy, iFGF23 was an independent predictor of the composite 
primary outcome defined as death, doubling of baseline serum creatinine and/or need for 
dialysis, even after adjustment for creatinine clearance and intact parathyroid hormone (100). 
One of the limitations of the two aforementioned studies was the relatively small sample size. 
However, this finding was confirmed in a large multicenter prospective study CRIC (Chronic 
Renal Insufficiency Cohort) involving 3879 CKD stages 2–4 patients with a median follow-
up of 3.5 years, high cFGF23 levels were independently associated with poor renal outcome 
(101). These studies were largely carried out in Caucasians or African Americans. Few if any 
studies have investigated the role of FGF23 in African CKD patients. 
1.8.2 FGF23 and cardiovascular outcome 
In the HOST (Homocysteine study), compared to patients with the lowest FGF-23 levels, 
patients in the highest quartile of baseline FGF23 had a hazard ratio of 2.58 for future 
cardiovascular events in univariate analysis. High levels of FGF23 remained a significant 
predictor of cardiovascular outcome, while vitamin D, calcitriol and PTH did not. Regarding 
the composite cardiovascular endpoint, elevated FGF23 was an independent predictor of 
myocardial infarction and lower extremity amputation (102). These studies have also shown 
an association between elevated levels of FGF23 in CKD and left ventricular hypertrophy, 
vascular calcification and mortality (101, 102). 
1.9 Vitamin D and CKD 
Vitamin D is mainly derived from dietary sources or synthesized by the skin from UVB light. 
It is first converted to 25(OH) D in the liver and subsequently activated to its active form 
known as 1, 25(OH) 2D3 (103).  Until recently, the final step of activation, 1α-hydroxylation 
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was thought to occur primarily in the kidney (104). However, emerging evidence continued 
to reveal that in addition to the kidney pathway for activation of 25 (OH) D, a peripheral 
autocrine (non-renal) pathway is also involved in calcitriol synthesis (105).  In fact, the 
hypothesis of extra renal 1α-hydroxylase had been proposed several years before the 
availability of calcitriol and its analogues. For example, studies have demonstrated that there 
were occasional anephric patients who had measurable blood levels of vitamin D metabolites 
(1α, 25-dihydroxyvitamin D3) following administration of vitamin D or 25 (OH) D3 (106, 
107).  Furthermore, recent epidemiological data and studies of the vitamin D receptor (VDR) 
knockout mouse have shown that the role of vitamin D is not solely restricted to its classical 
function of regulating calcium and phosphate homeostasis (108). Vitamin D, in the form of 
calcitriol, mediates a wide variety of cell differentiation around the body. The non-classical 
role of vitamin D includes regulation of the renin angiotensin system and the nuclear factor -
kappa B pathway which are commonly implicated in various disease pathological processes 
(109, 110). Furthermore, the emergence of the non-classical pathway has also given insights 
into the mechanisms behind the significant association between vitamin D deficiency and 
multiple chronic disease conditions such as cardiovascular disease, diabetes, malignancies 
and CKD (111). This has led to a special interest in the importance of addressing vitamin D 
deficiency particularly in CKD patients who are more susceptible to vitamin D deficiency.   
Therefore, it now advocated that having corrected the abnormal calcium/phosphate axis of 
the CKD patient that the nephrologist should also mitigate the wider effects of vitamin D 
insufficiency (105). 
1.9.1 Prevalence of vitamin D deficiency 
The comparison of epidemiological data on the prevalence of vitamin D deficiency is 
somewhat hampered by the lack of consensus on how to define vitamin D deficiency (112). 
However, the most widely acceptable cut off value for defining vitamin D deficiency is 
serum 25 (OH) vitamin D levels below 20 ng/ml, while patients with 25 (OH) D levels 
between 20 and 30 ng/ml are considered to be vitamin D insufficient (113).  Based on these 
cut off values vitamin D deficiency or insufficiency has been considered a global health 
problem affecting approximately 1 billion people worldwide (114). Studies have reported that 
40 -100 % of USA and European elderly men and women living in the community are 
deficient in vitamin D (111). Vitamin D deficiency is also common in countries with 
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abundant sunshine, when there is limited skin exposure to UVB sunlight. For example, 
studies from Saudi Arabia, India, and Lebanon, have reported that 30 to 50% of children and 
adults had 25 (OH) D levels under 20 ng/ml (115-117).  In Africa, although nationally 
representative data are sparse, a systematic review by Prentice et al. (118) revealed a 
collective prevalence of 25 (OH) D <25 nmol/l (10 ng/ml) between 5–20%.  Most of the 
African studies were conducted on healthy children and children with Ricketts, while a few 
were on healthy adults, pregnant and lactating women (119-121). In addition, various test 
methodologies were used in these studies and only three papers reported the use of the 
Vitamin D External Quality Assessment Scheme (DEQAS) which monitors 25 (OH) D assay 
performance. (118).  
Patients with CKD are more likely to have 25 (OH) D deficiency due to a reduction in the 
level of 1-α-hydroxylase available for the conversion of 25 (OH) D to active vitamin D. 
Other causes of vitamin D deficiency in CKD patients include urinary loss of vitamin D 
binding protein, reduced dietary intake due to uraemia, and increased levels of FGF23. 
Several studies have shown high prevalence of vitamin D deficiency ranging from 60- 80 % 
in patients with CKD. In a cross sectional study from the US involving patients with CKD 
stages 3 and 4, La Clair et al (122) reported that only 29 and 17% of patients with CKD stage 
3 and 4 respectively had adequate vitamin D status. They used much lower 25 (OH) D levels 
of < 10 ng/ml to define vitamin D deficiency and levels of 10-30 ng/ml as insufficiency. In 
another multicenter  cross sectional study from the United States, Wolf et al reported that 78 
%  of the study cohort had vitamin D deficiency defined as  serum 25 (OH) D  <30 ng ml−1 
and  18 %  of the study population was severely deficient  (serum 25 (OH) D  <10 ng ml−1) 
(123). The reported high prevalence of 25 (OH) D deficiency in these studies is in contrast 
with the Canadian study to evaluate early kidney disease (SEEK) which found that only 12 % 
of the participants with estimated GFR <20ml/min/1.73 m2 had vitamin D deficiency. The 
reason for this lower prevalence rate may be attributable to dietary habits in Canada and 
vitamin D supplementation of food. Furthermore, the high variations in the proportion of 
vitamin D deficiency across studies may be due to differences in ethnic distribution, degree 
of sun exposure, and utilization of different cut off values. In addition, differences in test 
methodologies may have also accounted for the observed variations.  For  example, 
significant 25 (OH) D intra and inter  variations have been reported with different auto 
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analyzers (124).  In our study HPLC, which is considered to be the gold standard for vitamin 
D measurement (125), was used to specifically measure 25 (OH) D3, and is less affected by 
vitamin D supplementation.  
In Africa, data on prevalence of vitamin D status in CKD population is sparse. In a recent 
cross sectional study from Senegal involving 46 haemodialysis patients, Seck et al. (126) 
reported that prevalence of vitamin D deficiency was 32.6% and 28 patients (60.8%) had 
vitamin D levels between 15 μg/l and 30 μg/l. This study was limited by small sample size 
which reduced the significance of their conclusion. 
1.9.2 Vitamin D levels and patients outcome in CKD 
In the Third National Health and Nutrition Examination Survey (NHANES III) involving 
15,068  participants,  de Boer et al. (127) reported a stepwise increase in the prevalence of 
albuminuria (8.9%, 11.5%, 13.7%, and 15.8%; P < 0.001) with decreasing quartiles of 
25(OH)D .  
In another prospective study involving clinically stable patients with stages 2–5 CKD, 25 
(OH) D independently predicted both time to death and progression to ESKD (128). Other 
well established clinical correlates of vitamin D deficiency are insulin resistance, 
cardiomyopathy and dysregulation of the immune system (128-131).  Therefore, co-existence 
of these conditions in patients with CKD who are already at risk of cardiovascular events is 
monumental. 
The relationship between vitamin D deficiency and increased mortality in ESKD was further 
supported by several observational studies that implicated the use of paracalcitol and 1, 25 D 
and 1α-hydroxylated-VD with better survival in CKD patients (132-134).  These studies were 
limited by the observational study design and thus the need for randomized controlled trials 
(RCTs) to further clarify the survival benefit from active and/or pre-active vitamin D.  
Interestingly, an association has also been established between active vitamin D analogues 
and reduction in proteinuria, likely through an interaction with the renin angiotensin 
aldosterone system (135). 
However, despite all the above aforementioned associated adverse clinical outcomes with 
vitamin D deficiency, little is known on vitamin D status in African CKD populations. 
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Therefore, one of our study objectives was to determine the vitamin D status in our patients 
and further explore its relationship with secondary hyperparathyroidism. 
1.10 Ethnic variations in biochemical markers of CKD-MBD 
The mechanism behind the existence of racial differences in the regulation calcium/ PTH/ 
calcitriol axis is largely unknown. However, it was proposed that blacks are susceptible to 
lower levels of 25 (OH) D, leading to increased parathyroid gland mass and secondary 
hyperparathyroidism. In addition, despite lower levels of 25 (OH) D, blacks have higher 
levels of 1, 25(OH) 2D3 and lower urinary calcium than whites. In a retrospective study 
involving 1367 haemodialysis patients, black race was independently associated with severe 
hyperparathyroidism. This study was limited by non-availability of data on vitamin D levels. 
Subsequently, other studies have consistently reported higher levels of PTH and lower levels 
of 25 (OH) D in blacks than whites.  The consequences of these abnormal markers of CKD 
have also been shown to differ across races and thus the need for race specific target values 
for these markers of MBD (11). For example, in a multi ethnic study of atherosclerosis 
(MESA) involving 6436 participants, 25 (OH) D deficiency was associated with increased 
risk of coronary heart disease in white but not in black Americans (136). A similar trend was 
found in the National Health and Nutrition Examination Survey (NHANES III), where  low 
25 (OH) D was associated with a higher risk of all-cause mortality in white compared to 
black  participants (137).  Furthermore, FGF23, which is now being considered as the 
principal mediator of secondary hyperparathyroidism, has also been shown to differ across 
races (8, 138). 
While there are considerable number of studies from developed countries that have looked at 
ethnic variations in markers of CKD-MBD among healthy population, there are only few 
studies from South Africa that have conducted a head to head comparison between White and 
Black populations. A previous study that dates back to 1997 reported no ethnic differences in 
serum intact PTH and calcitonin levels; however, Black women had lower serum 25 (OH)D 
compared to White women (19.3 vs 26.3 ng/ml, p = 0.0001)(139).  
The unestablished molecular basis for these racial variations in the markers of CKD-MBD 
highlighted a gap in knowledge and the need for further research in this field. Therefore, the 
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current study was embarked on, with the aim of exploring the extent of these differences in 
our patients and to assess whether genetic factors could partly explain these differences. 
1.11 Genetic basis for CKD-MBD 
1.11.1 VDR polymorphisms 
The VDR gene that encodes VDR is found on chromosome 12q12.14 and is made up of eight 
protein-coding exons (exons 2–9) and six untranslated exons (1a–1f). Single nucleotide 
polymorphisms (SNPs) and point mutations occur in the introns or the 3′ untranslated region 
(UTR) of the VDR gene (140). Alterations in these regions would lead to abnormal 
production of VDR.  The four common forms of VDR polymorphisms are (ApaI G>T 
[rs7975232], TaqI C>T [rs731236] and BsmI A>G [rs1544410]) which reside within an area 
between exons 8 and 9 with unknown function and in a unique linkage disequilibrium (LD)  
block spanning the VDR exons 3–9, while FokI T>C (rs10735810) resides in the non-coding 
exon (140). 
The VDR plays a vital role in mediating the effects of the biological active form of vitamin D 
(1, 25(OH) 2D3, therefore it is biologically plausible that variations in these receptors will 
modulate the consequences associated with vitamin D deficiency (141).  In 1994, Morrison et 
al. (142) were the first to report an association between VDR polymorphisms and bone 
metabolism. This report showed that the common allelic variants in the VDR encoding genes 
can predict differences in bone density in healthy individuals (142). Subsequently, several 
researchers have explored this relationship in CKD populations with emphasis on the 
calcium/ PTH/ calcitriol axis (143, 144). The BsmI polymorphism (BB genotype) has been 
associated with slower progression of secondary hyperparathyroidism and normal levels of 
calcitriol in predialysis CKD patients, and  lower levels of PTH in haemodialysis, and a better 
reduction in PTH levels in response to a single bolus of calcitriol therapy compared  to 
patients with bb genotype (144, 145).  However, contrary to earlier studies, findings from 
subsequent studies on the associations between VDR polymorphisms and markers of mineral 
bone disease have been inconsistent.  For instance, some studies reported no difference in 
PTH levels between the various BsmI genotypes (146, 147), while Chudek et al. revealed 
significantly lower levels of calcitriol in patients with the BB genotype (148). Similarly, 
some studies have linked other VDR polymorphisms to mineral bone metabolism in 
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haemodialysis patients. The VDR FokI polymorphism (FF genotype) was reported to be 
associated with higher PTH levels (149).  
Furthermore, the existence of racial disparities in abnormal markers of CKD-MBD and the 
better survival paradox in African Americans compared to white dialysis patients may be 
explained partly by the racial differences in the distribution of VDR polymorphisms and 
VDR receptor activation therapy.  Most of these studies were conducted on European, Asian 
and American CKD populations, while studies from Africa were largely on non-CKD 
populations. Therefore, in line with ongoing efforts to better understand the mechanisms 
behind racial disparities in markers of CKD-MBD, we aimed to explore the variations in the 
VDR polymorphisms between black and white African CKD patients and its relationship 
with biochemical markers of mineral bone disorders. 
1.12 Aims 
1. To determine the spectrum of CKD-MBD in South African CKD patients. 
2. To determine the association between biochemical markers of CKD-MBD and 
mortality in maintenance haemodialysis patients. 
3. To compare markers of mineral bone disease between black and white South African 
patients with CKD. 
4. To compare the association between FGF23 and traditional markers of CKD-MBD. 
5. To evaluate the relationship between VDR polymorphisms and biochemical markers of 
CKD-MBD. 
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CHAPTER 2: MATERIALS AND METHODS 
2.1 Study design, population and sites 
This was a cross -sectional multicenter study carried out from April 2015 to May 2016, 
involving two hundred and ninety three CKD patients from three renal units in Johannesburg, 
South Africa. The retrospective arm of this study involved two hundred and thirteen patients 
undergoing MHD from two dialysis centers in Johannesburg between January 2009 and 
March 2016.  Patients on maintenance haemodialysis were contacted on the days of their 
dialysis and, when confirmed eligible for enrolment, were given study information sheets and 
consent forms before recruitment. The pre dialysis patients were contacted on their clinic 
days. A comparative control arm of the study involved ninety apparently healthy participants 
without kidney disease.  
2.1.1   Sample size estimation 
Minimal sample size was determined using Fisher’s statistical formula.  
 Sample size (N) = Z
2
PQ  
                                 D
2
  
Z     =     1.96, that is normal standard deviation at 95% confidence interval 
P     =     Prevalence rate of CKD Mineral bone disorder  
Q     =     1-P                                     D = 0.05 Precision 
The prevalence (P) of CKD Mineral bone disease is 88.29%   based on the findings of Gosh 
B et al(1) . Hence, a prevalence of 88.29 % was used to calculate the sample size.
 
                               
  N   =   (1.96)
2 
x 0.883 x 0.117   = 158 
                         (0.05)
2
  
Therefore, a minimum of 158 patients with CKD will be enrolled. The ratio of study 
population to control was 2: 1. Thus a total of 80 healthy controls will be required for 
comparison. 
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2.1.2 Study sites 
Charlotte Maxeke Johannesburg Academic Hospital (CMJAH), Wits Donald Gordon Medical 
Center and Glynwood Hospital, South Africa 
2.1.3 Inclusion Criteria  
Patients with established CKD stages 3-5D, aged ≥ 18 years who gave informed consent were 
enrolled. 
2.1.4 Exclusion Criteria   
Patients with active or chronic liver disease, on treatment with steroids or bisphosphonates, 
and having malignancies were excluded. In addition, we excluded Indian and mixed races to 
allow for a proper comparison between black and white patients. 
2.1.5 Ethical consideration 
 The research protocol was approved by the Health Research and Ethics committee (HREC) 
of the University of the Witwatersrand; clearance certificate number M141016. Written 
informed consent was obtained from each patient before enrolment into the study. 
2.2 Screening and evaluation protocol 
2.2.1 A structured questionnaire was used to obtain patients’ demographic characteristics, 
blood pressure measurements, co-morbid disease, underlying aetiology of CKD and 
medication history related to CKD-MBD. Determination of race was based on self-report by 
the participants. 
2.2.1 Blood collection and preparation 
Whole blood samples were collected into plain separator vacutainer tubes (for serum), and 
ethylene diamine tetra acetic tubes (for plasma). Samples were left to clot and then 
centrifuged at 5000 rpm at 4
 o
C
 
  for 10 minutes. Both serum and plasma were aliquoted into 
1.5ml micro centrifuge tubes and stored at -80 
o
C.  Whole blood collected for VDR 
genotyping was stored at −20 oC. 
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2.3 Laboratory measurements 
 2.3.1 Plasma intact PTH  
Plasma intact PTH was measured by an electrochemiluminescence immunoassay (ECLIA) 
run on a Cobas 6000 auto analyzer (Roche Diagnostics, Mannheim, Germany). The test 
methodology entails adding 50 µL of sample to a biotinylated monoclonal PTH-specific 
antibody, and monoclonal PTH-specific antibody labeled with a ruthenium. Addition of 
streptavidin-coated micro particles enhance the complex bound to the solid phase, and the 
unbound substances are washed off. A voltage is then applied to the electrode to generate 
chemiluminescent emission. There is a direct relationship between the amount of PTH in the 
sample and the generated chemiluminescent emission which is measured by a 
photomultiplier.  
2.3.2 Fibroblast growth factor 23 
 Fibroblast growth factor 23 was measured using a sandwich based enzyme-linked 
immunosorbent assay kit from EMD Millipore Corporation (Billerica, MA, USA); assay 
lower limit of detection was 3.2 pg/ml. 50 µL of plasma samples were added to the 
appropriate wells in addition to 100 µL of conjugate antibody. The plate was covered with a 
sealer and allowed to incubate for 2 hours on a microliter plate shaker. The solutions were 
then decanted from the wells and washed three times with a diluted wash buffer.  100 µL of 
detection antibody was then added to all wells and further incubated for 1 hour on a plate 
shaker. The solutions were decanted from the wells and washed three times with a diluted 
wash buffer. The washing step was repeated after adding 100 µL of enzyme solution with 30 
minutes incubation period. Finally, 100 µL of substrate solution was added to each well to 
stop the reaction. Optical density at 450 nm was measured on an ELx800 microplate reader 
(BioTek, Winooski, VT, USA). 
2.3.3 Plasma 25 (OH) vitamin D 
Plasma 25(OH) D was measured using the high performance liquid chromatography (HPLC) 
kit (Recipe, Munich, Germany).  HPLC was used to selectively measure 25-(OH) vitamin D2 
and 25-(OH) vitamin D3 at a wave length of 264nm. The intra and inter assay coefficients of 
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variation (CVs) were < 5%.  Our institutional laboratory is a participating member in the 
vitamin D external quality assurance scheme (DEQAS). In this study, 25(OH) D3 was used 
as a marker of vitamin D status to avoid confounding of the results from exogenous vitamin 
D supplementation.  
2.3.4 Determination of serum calcium, phosphate and alkaline phosphatase 
Serum calcium, phosphate and alkaline phosphatase were measured using the ADVIA 1800 
centaur auto analyzer (Siemens Diagnostics, Tarrytown, USA), and their test principles were 
as follows: 
In alkaline medium calcium ions reacts with 0-cresolpthalein complex one to form a violet 
colour that is measured at 545/658nm. 
In an acidic medium created by sulphuric acid, inorganic phosphate reacts with ammonium 
molybdate to form phosphomolybdate complex which is measured at 340/658nm. 
2.3.5 Determination of serum creatinine and glomerular filtration rate 
Creatinine was measured by a modified Jaffe reaction method which is based on a colour 
formation from a reaction of creatinine with picric acid alkaline medium. The creatinine 
assay is traceable to isotope dilution mass spectrometry (IDMS).  The glomerular filtration 
rate (GFR) was estimated using the four- variable Modified Diet Renal Disease (MDRD) 
equation(2) : GFR (in mL/min per 1.73 m
2
) = 175 × SCr (exp[−1.154]) × Age (exp[−0.203]) 
× (0.742 if female) × (1.21 if black).  
The rationale behind the use of MDRD in this study is based on the fact that our study 
population are patients with already established CKD with GFR < 60mls/min per 1.73 m2, 
and  MDRD  study equation is  appropriate  for patients with CKD stages 3 and 4(3). One of 
the limitations of MDRD is in underestimation of GFR in early stages of CKD. Although the 
proposed CKD- Epidemiology Collaboration (CKD- EPI) equation accounts for this 
limitation, it performs better in healthy population (3). Therefore, the  MDRD and CKD-EPI 
equations perform equivalently in CKD stages 3-5. 
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2.4 Genotyping 
DNA was extracted from whole blood using the Maxwell DNA purification kit (Promega 
AS1010, USA). The DNA concentrations and purity were determined using NanoDropTM 
2000 spectrophotometer (Thermo Scientific, USA) at A260 and A260/A280 ratios. Salting 
out method was used to re extract DNA from samples with low yield (<10 ng/ul). 
Briefly, the salting out method involved suspending buffy coats of nucleated cells in 15 mls  
polypropylene tubes containing  3mls of nucleic lysis buffer (1% SDS; 2 mM EDTA) and 2 
mg/ml proteinase K. The cell lysate was treated overnight with proteinase K at 37
0
C.  The 
tubes were vigorously shaken following addition of sodium chloride and subsequently 
incubated on ice for five minutes. The pellets were washed with 70 % cold ethanol  and spun  
at 800 rpm for 20 minutes  to remove the excess salt used in precipitating the DNA. The 
DNA pellets were  finally,  dissolved in 100 mL of 10 mM TrisHCl, pH 8 prior to 
quantification. 
The thermocycling condition involved initial denaturation step at 95 °C for 3minutes, 
followed by 40 cycles of denaturation at 95 °C for 15 seconds ,  annealing at 65°C (67  °C  
for Apa I)  for 20 seconds and a final extension at 72  °C for 1 minute. 
  DNA products were amplified using appropriate primers as shown  in Table 2.1. 
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Table2. 1: Primers, restriction enzymes and annealing temperatures 
Gene Primer Enzymes Allele  Annealing 
temperature  
ApaI F:5CAGAGCATGGACAGGGAGCAA
G 3’  
R:5’GCAACTCCTCATGGCTGAGGT
CTCA 3’ 
Apa I  (New 
England 
Biolabs) 
AA(TT): 740 
bp.  Aa(TG):740 
bp, 520bp and  
220bp 
aa(GG) 520bp, 
220bp. 
65 
0
C 
BsmI F:5’CAACCAAGACTACAAGTACCG
CGTCAGTGA 3’   
R:5’AACCAGCGGGAAGAGGTCAA
GGG 3 ‘ 
BsmI  (New 
England 
Biolabs) 
BB (AA): 
825bp. Bb 
(AG):825bp, 
650 bp and 175 
bp. 
bb(GG):650 bp, 
175bp 
65 
0
C 
FokI F:5’AGCTGGCCCTGGCACTGACTC
TTGCTCT 3’  
R:5’ATGGAAACACCTTGCTTCTTC
TCCCTC 3’ 
FokI ( New 
England 
Biolabs) 
FF(CC): 265 bp 
Ff(CT) 265bp, 
196 bp and 69 
bp. 
ff(TT):196bp,69
bp 
67 
0
C 
TaqI F:5’CAGAGCATGGACAGGGAGCA
AG 3’  
 
R:5’GCAACTCCTCATGGCTGAGGT
CTCA 3’ 
TaqI ( New 
England 
Biolabs 
TT(TT): 495bp, 
245bp 
Tt(TC): 495bp, 
290bp,245bp, 
and 205 bp. 
Tt(CC):290bp,2
45bp, and 205 
bp 
65 
0
C 
 
 The PCR products were then digested with enzymes ApaI, BsmI, FokI, and TaqI (New 
England Biolabs, Beverly, MA, USA) according to the supplier’s protocol. Digestions for   
BsmI and TaqI were at 65 
0
C left overnight, and 3hrs at 25 
0
C for ApaI, while FokI was 
incubated at 37 
0
C for 3 hrs. Restricted products were electrophoresed on either 10% 
polyacrylamide or 1.5% agarose gels and then visualized by the Gel Doc TM EZ imager 
(Bio-Rad systems, USA). Genotypes were scored based on the presence or absence of a 
restriction site for the enzymes BsmI, ApaI, and TaqI at the 3′ untranslated region and FokI at 
the N-terminal region of the gene. 
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2.5 Statistical analysis 
Detailed description of statistical methods are provided in the in the methods section of each 
manuscript. 
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                                     CHAPTER 3: MANUSCRIPT 1 
Biochemical markers of mineral bone disorder in South African patients on 
maintenance haemodialysis 
ABSTRACT 
Background: Despite the high mortality and morbidity associated with abnormalities in 
mineral and bone metabolism in haemodialysis patients, there are limited data on the pattern 
of mineral bone disorder in African CKD populations. Therefore, the purpose of this study 
was to describe the pattern of mineral bone disease by evaluating biochemical parameters in 
patients on maintenance haemodialysis (MHD). 
Methods: We evaluated the serum/plasma intact parathyroid hormone (iPTH), corrected 
calcium, phosphate, total alkaline phosphatase (TAP) and 25 (OH) D levels of two hundred 
and seven patients undergoing MHD at two dialysis centers in Johannesburg. 
Results: The MHD patients (133 men, 74 women) had a mean age of 54.5±15.6 years with a 
median dialysis vintage of 24 months (IQR, 12-48) and a mean kt/V of 1.45±0.28. The 
prevalence of hyperparathyroidism (iPTH>150 pg/mL),hyperphosphataemia, hypocalcaemia 
and 25(OH) D deficiency (<30 ng/mL) was 73.4%, 57.0%, 20.3% and 80.7 % respectively. 
The combination of markers of bone turnover (iPTH>150pg/mL and TAP> 112 U/L) 
suggestive of high turnover bone disease, was present in 47.3 % of the study population. In 
multiple regression analysis, the odds ratio for developing secondary hyperparathyroidism 
with hypocalcaemia and hyperphosphataemia were 5.32 (95% CI 1.10 - 25.9, P <0.05) and 
3.06 (95 % CI 1.15 - 8.10, P <0.05) respectively. 47.3 % of MHD patients had iPTH within 
the recommended KDIGO guidelines.  
Conclusion: Secondary hyperparathyroidism and 25 (OH) D deficiency were common in our 
haemodialysis patients. Hypocalcaemia and hyperphosphataemia were strong predictors for 
developing secondary hyperparathyroidism. 
Keywords: Biochemical markers, guide lines, mineral bone disorder, haemodialysis 
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3.1 Introduction 
Chronic kidney disease-mineral bone disorder (CKD-MBD) is now defined as a “systemic 
disorder of mineral and bone metabolism due to CKD manifested by either one or a 
combination of the following: (i) abnormalities of calcium, phosphorus, parathyroid hormone 
(PTH), or vitamin D metabolism; (ii) abnormalities in bone turnover, mineralization, volume, 
linear growth, or strength; or (iii) vascular or other soft tissue calcification and that the term 
renal osteodystrophy should exclusively be used to describe disorders in bone morphology 
associated with CKD”(1, 2). Although bone biopsy is the gold standard for adequately 
describing the spectrum of CKD-MBD, it is less frequently utilized in clinical settings 
because of associated constraints. It is an invasive and cumbersome procedure that requires 
highly skilled personnel to interpret the obtained tissue samples. Therefore, clinicians largely 
depend on the biochemical parameters for monitoring and management of this important 
clinical entity that is associated with adverse clinical outcomes in CKD patients. In addition, 
the above aforementioned internationally acceptable definition has led to the ease of 
diagnosing CKD-MBD and allows valid comparison of studies in this field. 
 In 2009, through extensive review of the literature the KDIGO (Kidney Disease Improving 
Global Outcomes) guideline work group came up with guidelines to assist clinicians in the 
management of patients with CKD-MBD(2). The guidelines were largely based on studies 
conducted on Asian, European and American populations. These guidelines were adopted by 
many African countries despite existence of racial differences in PTH, vitamin D and 
phosphorus as demonstrated by several studies (3-5). The lack of use of literature from Africa 
is likely due non availability of robust data from these regions. Therefore, information 
obtained from this present study will add to the existing paucity of data on African patients 
with CKD-MBD. 
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3.2 Materials and Methods 
3.2.1 Participants and study design 
This was a cross sectional descriptive study involving two hundred and seven patients 
undergoing MHD (from June 2009 to April 2016) at two dialysis centers in Johannesburg, 
aged ≥ 18 years with complete data for analysis. Exclusion criteria included patients with 
active malignancy, active liver disease, and patients on medications such as bisphosphonates 
or warfarin. Demographic and clinical data collected were age, gender, history of 
medications, underlying aetiology of CKD, duration of haemodialysis and blood pressure 
measurements. The research protocol was approved by the Health Research and Ethics 
committee (HREC) of the University of the Witwatersrand. 
3.2.2 Laboratory measurements  
Plasma intact PTH was measured by an electrochemiluminescence immunoassay (ECLIA) 
run on a Cobas 6000auto analyzer (Roche Diagnostics, Mannheim, Germany; reference range 
10-65 pg/mL). 
Serum 25 (OH) D was measured by a chemiluminescentmicro particleimmunoassay (CMIA) 
technique (Abbott Laboratories, Abbott Park, Illinois, US). Reference ranges: < 10 ng/mL as 
severe deficiency, 10-29 ng/mL as  moderate deficiency, 30-100 ng/ mL as sufficiency and > 
100 ng/ mL as toxic(6). 
Calcium, Phosphate and Alkaline phosphatase were measured using the ARCHITECT C8000 
auto analyzer (Abbot Laboratories, Abbott Park, Illinois, US). Other biochemical parameters 
were determined using routine laboratory techniques. 
Laboratory reference range for calcium and phosphate were as follows: 
Calcium (2.12-2.50 mmol/L) 
Phosphate (0.79-1.45mmol/L). 
Based on the above reference values and KDIGO recommendations the following definitions 
were employed in this study:  
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Hyperparathyroidism and hypoparathyroidism were defined as intact PTH >150 pg/ml and 
PTH < 15 pg/ml respectively. 
Hyperphosphataemia and hypophosphataemia were defined as phosphate levels >1.45 
mmol/L and <0.80mmol/L respectively. 
Hypercalcaemia and hypocalcaemia were defined as calcium levels >2.50mmol/l and 
<2.12mmol/l respectively. 
3.2. 3 Statistical analysis 
Patients’ demographic and baseline characteristics are presented as means and standard 
deviations (SD) or medians (Interquartile ranges) depending on the distribution of the 
variable, while categorical data were presented as proportions or percentages. The means of 
biochemical parameters were compared between diabetic and non-diabetic patients using an 
independent t–test and Pearson’s or Fisher’s exact test was utilized for proportion 
comparisons. Associations between log transformed PTH and other biochemical parameters 
were assessed by multiple linear regression analyses following significant associations 
obtained from univariate regression analyses. A logistic regression model was used to 
evaluate the effect of other biochemical parameters on the odds of developing secondary 
hyperparathyroidism. A p-value of less than 0.05 was considered statistically significant at 
the 95% confidence interval. All analyses were performed using STATA version 12 (STATA 
Corp., TX, and USA).  
3.3 Results  
Two hundred and seven MHD patients (133 men, 74 women) were enrolled. Their mean age 
was 54.5±15.6 years with a median dialysis vintage of 24months (IQR, 12-48) and a mean 
Kt/V of1.45±0.28.  Fifty six (27.1%) of the study population were diabetic. Medications 
received included calcium carbonate 154 (74.4%), alfacalcidol 132 (63.8%), cholecalciferol 
45(21.7%) and 12 (5.8%) were on cinacalcet (Table 1). The majority of the patients were on 
three times weekly 4 hr sessions of haemodialysis. 
Table 3.2 shows a comparison of biochemical parameters and distribution of CKD-MBD 
abnormalities between diabetic (n=56) and non-diabetic (n=151) patients. Diabetic patients 
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had significantly lower mean 25(OH) D as compared to non-diabetic patients. Other 
biochemical parameters were comparable between the groups. 
The overall prevalence of hyperparathyroidism (iPTH>150pg/mL), hyperphosphataemia, 
hypocalcaemia and 25 (OH) D deficiency (<30 ng/mL) was 73.4%, 57.0%, 20.3% and 80.7 
% respectively. The combination of markers of bone turnover (iPTH>150pg/mL and TAP > 
112 IU/L) suggestive of high turnover bone disease, was present in 47.3 % of the study 
population (Table 3.2).  
Patients within KDIGO-recommended targets for calcium, phosphate and PTH were 63.8%, 
37.7 %, and 47.3% respectively (Table 3.3). 
In logistic regression analysis, hypocalcaemia and hyperphosphatasemia were identified as 
predictors of hyperparathyroidism (p <0.05) (Table 3.4).  
Univariate linear regression revealed a significant association between log transformed PTH 
and phosphate (r
2
=0.03, p=0.007), calcium (r
2
=0.02, p=0.03), TAP (r
2
=0.05, p=0.006), 25 –
OH vitamin D (r
2
=0.05, p=0.005). When including all these parameters in a multiple 
regression analysis, only phosphate and 25 (OH) D remained significantly correlated with log 
PTH; p= 0.02 and 0.04 respectively. 
3.4 Discussion 
In agreement with previous studies from Africa and developed countries (7-9), this study has 
revealed a high prevalence of derangements of biochemical markers of mineral bone 
disorder. Based on the cut-off values utilized by this study, hyperparathyroidism (PTH>150) 
was present in 73.4% of the patients and 37% with a stricter cut-off value of 585 ng/ml (9 
times the upper normal of our laboratory assay). However, because of the dynamic nature and 
complexity of bone homeostasis it is difficult to rely on one biochemical marker as a 
surrogate test of bone formation (10). Therefore, utilizing both PTH and TAP, though not as 
specific as bone specific alkaline phosphatase, almost half of our study population was 
identified as having high bone turn over. In addition, the 2009 Kidney Disease Improving 
Global Outcomes (KDIGO) guidelines recommended  measurement of TAP every 12 months 
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in CKD 4-5D (2), and the additional cost in routinely  utilizing bone specific alkaline 
phosphatase to monitor the management of CKD-MBD has not been justified. 
Comparison of epidemiological data on prevalence of vitamin D deficiency is being 
hampered by lack of consensus on how to define this deficiency. However, the widely 
accepted definition includes serum 25 (OH)  D level below 20 ng/ml while patients with 25 
(OH) D levels between 20 and 30 ng/ml are considered to be vitamin D insufficient(6).  One 
of the striking results of our study was the high prevalence (80.7%, N=161) of inadequate 
vitamin D status in our study population and of which 29.2 % were severely vitamin D 
deficient (<15 ng/m/). These findings are consistent with previous cross sectional studies in 
Americans (11-13). In contrast to our finding regarding severe deficiency,  Jabbar et al(14) 
reported vitamin D deficiency  (<15ng/ml) in 90 % of the patients and attributed it to the low 
vitamin D content in the  traditional (vegetarian) Indian diet. Diabetic patients had 
significantly lower mean levels of 25(OH) D and inadequate vitamin D compared to non-
diabetic patients. This finding is in line with previous studies from Europe and Asia (15, 16) 
in which a high prevalence of vitamin D deficiency was demonstrated in > 90% of the 
diabetic patients. This remarkably high prevalence could have been due to proteinuria, which 
is more common in diabetic nephropathy and is associated with heavy urinary loss of vitamin 
D binding protein, as proposed by previous studies (16, 17).  However, in general, factors that 
could account for vitamin D deficiency in patients with CKD include reduced dietary intake, 
loss of vitamin D binding protein in urine and increased levels of FGF23 in CKD (16). 
In an attempt to reduce the adverse clinical outcomes associated with CKD-MBD several 
guidelines were proposed by various regional and global bodies (2, 18, 19). Based on the 
recommended target ranges by the widely adopted KDIGO guidelines,(2) more than half of 
our study population had serum phosphate levels above the target level (Phosphate 
>1.45mmol/L). This is similar to other large observational multicenter studies [Dialysis 
outcomes and practice patterns (DOPPS I) (20)and a study from Italy (21)] that both reported  
serum phosphate of >5.5mg/dL(1.78mmol/L) in 51.6% of the patients. Despite the advances 
in haemodialysis, with the invention of more effective dialysis membranes and the use of 
ultrapure dialysate, the removal of phosphate is still inadequate. The conventional HD (3 
times per week, 4 h session) removes approximately 2.3-2.6g/wk compared to 4.5-4.9g by the 
nocturnal HD (8hrs/day) (22). The majority of our patients are on conventional HD with a 
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very few of them (9.2%) on nocturnal dialysis. Therefore, one of the reasons that could have 
accounted for the high prevalence of hyperphosphataemia is the ineffective removal of 
phosphate by conventional haemodialysis. In addition, calcium carbonate which is used as 
phosphate binder in most of our patients has lower phosphate binding capacity compared to 
non-calcium based phosphate binders. Other notable patient factors are the adherence to both 
medications and dietary restriction. 
In this study, according to the KDIGO recommendation that PTH should be maintained 
between 2-9 times the upper limit of normal range (i.e 130-585 pg/ml), the proportion of 
patients within the target guideline level was higher than that reported by previous studies (7, 
20, 23). Their reported lower values were likely due to utilization of KDOQI guidelines with 
narrower recommended ranges of PTH (150-300pg/ml).  
Interestingly, a significant percentage of our patients had their corrected calcium within the 
KDIGO recommended guidelines which is higher than the report from DOPPS II 42.5 % 
(20). Re analyzing our data based on KDOQI the number still remains slightly higher 
(54.1%). Overall, the discrepancy between the current study and other previous studies may 
likely be due to differences in the use of phosphate binders, dialysate calcium concentration 
and dietary phosphate intake.  
In keeping with previous studies (24), logistic regression analysis revealed hypocalcaemia 
and hyperphosphateamia as predictors of hyperparathyroidism. This further supports the 
classical role of hyperphospataemia and hypocalcaemia in the pathogenesis of CKD-MBD. In 
addition, we found phosphataemia to have remained closely related to log-transformed PTH 
in multivariate linear regression. 
The strength of our study is the larger sample size compared to other previous studies from 
Africa (7, 9, 25). 
The limitations of our study include: first, the lack of bone biopsy to definitively describe the 
patterns of CKD-MBD in our patients. However, studies have shown a good association 
between biochemical markers and histological findings (26, 27). Second, this was a cross 
sectional study so we could not establish the temporal relationships between the biochemical 
markers and phosphate binders. Thus there is a need for a longitudinal study to assess these 
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relationships. Nonetheless, findings from this study have provided us with important insights 
on the spectrum of CKD-MBD in African MHD patients. 
In conclusion, abnormalities of biochemical markers of mineral bone disorder were common 
in our MHD patients and moderately large proportion of the patients was outside the KDIGO 
recommended target levels. However, due to the existence of racial differences in PTH, 
25(OH) D and phosphorus levels it is unclear whether these guidelines could be extrapolated 
to African MHD patients.  Therefore, there is a need for large multicenter studies in Africa to 
support management of CKD-MBD in African patients with CKD. 
Conflict of interest:  The authors declare they have no conflict of interest. 
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Table 3. 1: Study population characteristics 
Parameters Results 
Age (years) 54.5± 15.6 
Gender, n (%)  
Male 133(64.23%) 
Female 74(35.75%) 
Diabetes, n (%) 56(27.1%) 
Race, n (%)  
Black 121(58.5%) 
Non Black 86(41.5%) 
Serum creatinine(µmmol/L) 695.48± 278.61 
Serum calcium(mmol/L) 2.28±0.22 
Serum phosphate(mmo/L) 1.59±0.56 
Intact PTH(pg/ mL) 451.85±430.38 
Plasma 25 -OH vitamin D(ng/ml) 21.16±10.71 
Haemoglobin(g/dL) 10.26± 2.0 
Albumin(g/L) 31.91± 6.12 
Systolic BP(mmHg) 134.18±21.81 
Diastolic BP(mmHg) 72.03±13.74 
Alkaline phosphatase(UI/L) 143.21± 115.26 
Kt/V 1.45±0.28 
Dialysate Calcium(mmol/L)  2.22±0.09 
Dialysis vintage(months) 24(12-48) 
Calcium carbonate use n (%) 154(74.4%) 
Cinacalcet n (%) 12(5.8%) 
Alfacalcidol n (%) 132(63.8%) 
Cholecalciferol n (%)  45(21.7%) 
Continuous variables are presented as mean± standard deviation and categorical data as frequencies (percentages). BP= blood pressure 
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Table 3. 2: Comparison of parameters/distribution of mineral bone disorder between 
diabetic and non – diabetic patients 
Variables ALL(N=207) DM(n=56) Non 
DM(n=151) 
P 
Intact PTH 451.9±430.4 439.1±489.5 454.70±413.1 0.83 
 Corrected Calcium(mmol/L) 2.28±0.22 2.30±0.21 2.275±0.22 0.41 
Phosphate(mmol/L) 1.59±0.56 1.52±0.51 1.61±0.58 0.25 
Alkaline phosphatase(IU/L) 143.21± 115.26 155.77±131.72 139.15±109.41 0.41 
Hyperparathyroidism (>150 pg/ml) 152 (73.4%) 38 (67.9%) 114 (75.5%) 0.84 
Hypoparathyroidism (<10 pg/ml) 2 (9.7%) 1(1.79%) 1 (6.6%) 0.44 
Hyperphosphataemia(>1.45mmol/l) 118(57.0%) 27 (48.2%) 91 (60.3%) 0.19 
Hypophosphataemia(<0.80mmol/L) 11(5.3%) 4 (7.1%) 7 (4.6%) 0.44 
Hypercalcaemia (>2.50mmol/L) 26(12.6%) 8(14.3%) 18 (11.9%) 0.53 
Hypocalcaemia(<2.12mmol/L) 42 (20.3%) 10 (17.9%) 32 (21.2%) 0.91 
ALP (>112IU/L) 103 (49.8%) 33 (58.9%) 70 (46.4%) 0.76 
25-Hydroxyvitamin D (N=161)     
25 ( OH) D(ng/ml) 21.16±10.71 18.12±12.77 22.21±9.82 0.04 
(<30 ng/ml) 130 (80.7%) 35 (92.1%) 95 (77.2%) 0.04 
(<15ng/ml) 47 (29.2%) 16 (42.1%) 31 (25.2%) 0.03 
PTH>150 & TAP>112 98 (47.3%) 24 (42.7%) 74 (49.0%) 0.58 
Continuous variables are presented as mean± standard deviation and categorical data as frequencies (percentages). PTH= Parathyroid hormone, TAP= total alkaline 
phosphatase, 
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Table 3. 3: Distribution of patients achieving recommended guideline targets 
Guidelines Below target Within target Above target 
KDIGO    
PTH(2-9× upper normal range ) 44(21.3%) 98(47.3%) 65(31.4%) 
Calcium(within normal range) 48(23.1) 132(63.8%) 27(13.0%) 
Phosphate(within normal range) 11(5.3%) 78(37.7%) 118(57.0%) 
NKF KDOQI    
PTH(150-300 pg/mL) 51(24.6%) 54(26.1%) 102(49.3%) 
 corrected calcium(8.9-9.5 mg/d L) 32(14.5%) 112(54.1%) 63(30.4%) 
Phosphate(3.5-5.5mg/dL)) 35(16.9%) 104(50.2%) 65(31.4%) 
KDIGO, Kidney Disease Improving Global Outcomes; NKF KDOQI, National Kidney Foundation Kidney Disease Outcome Quality 
Initiative. 
 
Table 3. 4: Logistic regression analysis for predictors of hyperparathyroidism 
Variables Odds ratio 95 CI P-values 
Phosphate 3.06 1.15-8.10 0.02 
Calcium 5.32 1.10-25.9 0.03 
Alkaline phosphatise 1.67 0.66-4.29 0.28 
Diabetes mellitus 0.60 0.19-1.84 0.37 
Age 0.76 0.25-2.33 0.64 
25(OH)  D 0.39 0.10-1.60 0.20 
CI, confidence interval; covariates were by categories, Age≥ 65 years versus<65 years, phosphate >1.45 mmol/l versus≤1.45mmol/l, 
calcium<2.12mmol/l versus≥2.12mmol/l, Alkaline phosphatase>112 UI/L versus ≤112 UI/L, 25 (OH) D <30ng/ml versus≥ 30ng/ml,  
Diabetes mellitus versus No diabetes. 
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                                           CHAPTER 4: MANUSCRIPT 2 
High serum alkaline phosphatase, hypercalcaemia, race and mortality in South 
African maintenance haemodialysis patients. 
ABSTRACT 
Background 
Studies relating to associations between high alkaline phosphatase, altered markers of mineral 
bone disorder and increased mortality in maintenance haemodialysis patients (MHD) patients 
are mainly from Europe, America and Asia. However, little is known on the existence of this 
association in African MHD patients. Therefore, the aim of this study was to determine the 
relationship between serum total alkaline phosphatase (TAP) and mortality in African MHD 
patients.  
Patients and Methods  
The study enrolled a total of 213 patients on MHD from two dialysis centers in Johannesburg 
between January 2009 and March 2016. Patients were categorized into a low TAP group 
(≤112 U/L) versus a high TAP group (>112 U/L) based on median TAP of 112 U/L. Using 
multivariate Cox regression analysis the impact of serum TAP on the primary outcome 
(death) was assessed.  
Results  
The MHD patients (136 men, 76 women) had a mean age of 54.5±15.6 years with a median 
dialysis vintage of 24 months (IQR, 12-48) and a mean Kt/V (single pool) of 1.44±0.3.  
During the follow up period of 7 years, there were 55 (25.8%) deaths. After adjusting for 
cofounders  such as age, other markers of bone disorder and co morbidity (diabetes mellitus), 
patients in the high TAP group had significantly higher risk of death compared to patients in 
the low TAP group (hazard ratio, 2.50; 95% CI 1.24-5.01, p=0.01). Similarly, serum calcium 
>2.75 mmol/L was associated with increased risk of death compared to patients within levels 
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of 2.10-2.37 mmol/L (HR 6.34, 95% CI 1.40-28.76; P=0.02). The HR for death in white 
patients compared to black patients was 6.88; 95% CI 1.82-25.88; p=0.004.  
Conclusion 
High levels of serum alkaline phosphatase, hypercalcaemia and white race are associated 
with increased risk of death in MHD patients. 
Key words: Alkaline phosphatase, calcium, death, maintenance haemodialysis, race. 
 
4.1 Introduction 
Prior to the availability of commercial intact parathyroid hormone (PTH) assays, serum total 
alkaline phosphatase (TAP) measurements were used as one of the surrogate markers of high 
bone turnover that was utilized in the management of chronic kidney disease mineral and 
bone disorder (CKD-MBD) (1). Subsequently, in 2003 the Kidney Disease Outcome Quality 
Initiative (KDOQI) guidelines on CKD-MBD made no recommendations regarding the use of 
alkaline phosphatase and this has made it a less preferred marker to PTH. However, in 2009 
the Kidney Disease Improving Global Outcomes (KDIGO) guidelines recommended 
measurement of TAP every 12 months in CKD 4-5D(2) and more recently evidence 
continued to emerge on the importance of higher levels alkaline phosphastase in the 
pathogenesis of vascular calcification via hydrolysis of pyrophosphate which is a potent 
inhibitor of vascular calcification (3-5). This was further supported by a study that showed 
elevated levels of alkaline phosphatase, independent of PTH, calcium or phosphorus as 
predictor of coronary artery calcification in haemodialysis patients (6). Interestingly, in a 
recent secondary analysis of the handling erythropoietin resistance with oxypentifylline 
(HERO) trial, high levels of alkaline phosphatase were also associated with erythropoietin 
stimulating agent hypo responsiveness (7). These findings may likely explain the unclear 
pathophysiologic link between high serum alkaline phosphatase and mortality in 
haemodialysis patients (6). 
Although the role of racial disparities in adverse clinical outcomes remains controversial and 
inconclusive, some studies have demonstrated survival benefits attributable to race in patients 
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undergoing MHD (8, 9). In addition, the impact of these biochemical abnormalities have been 
shown to differ across race and thus the need for race specific target values for these markers 
of mineral bone disorder (10, 11). 
Therefore, the aim of this study is to determine if there is a link between high serum alkaline 
phosphatase and mortality in African MHD patients.  
4.2 Patients and Methods 
This study was a retrospective review of patients undergoing MHD from two dialysis centers 
in Johannesburg between January 2009 and March 2016. A total of 213 patients aged ≥ 18 
years with available baseline line variables of interest were included. Exclusion criteria 
included patients with missing important data for analysis, being on dialysis for less than 
three months, having active or chronic liver disease and having malignancies. In addition, we 
excluded Indian and mixed races to allow for a proper comparison between black and white 
patients. Retrieved data included patients’ demographic characteristics, blood pressure 
measurements, duration on haemodialysis, co-morbid disease and medication history related 
to CKD-MBD. Determination of race was based on self-report by the participants. 
Patients were categorized into the low TAP group (≤112 U/L) versus the high TAP group 
(>112 U/L) based on median TAP level of 112 U/L. Secondary analysis involved exploring 
the relationship between race, other markers of mineral bone disorder, and primary outcome. 
In line with a previous study (12) total calcium levels were categorized into four categories 
with the KDOQI target range as the reference category. Based on the KDIGO CKD-MBD 
guidelines, PTH was divided into three categories. 
The primary outcome of this study was death and events other than death were censored and 
this included kidney transplantation, loss to follow–up, or still undergoing haemodialysis at 
the end of the study. 
Laboratory measurements 
Patients’ baseline biochemical parameters (within the first three months of initiating dialysis) 
were assessed.  Most of the biochemical markers were measured monthly except for quarterly 
PTH. Plasma intact PTH was measured by an electrochemiluminescence immunoassay 
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(ECLIA) run on a Cobas 6000 auto analyzer (Roche Diagnostics, Mannheim, Germany; 
reference range is 10-65 pg/mL). Serum 25 (OH) D was measured by a chemiluminescent 
micro particle immunoassay (CMIA) technique run on the ARCHITECT C8000 auto 
analyzer (Abbott Laboratories, Abbott Park, Illinois, US). Reference ranges: < 10 ng/mL  as 
severe deficiency, 10-29 ng/mL as  moderate deficiency, 30-100 ng/ mL as sufficiency and > 
100 ng/ mL as toxic. 
Serum calcium, phosphate and alkaline phosphatase were measured using the ARCHITECT 
C8000 auto analyzer (Abbot Laboratories, Abbott Park, Illinois, US).  The corrected calcium 
was determined using the formula: corrected calcium (mmol/L) = calcium measured ( 
mmol/L) + 0.02 [40-albumin (g/L)]. Total alkaline phosphatase reference range is 53-128 
U/L. 
Plasma albumin was measured by colorimetric (bromocresol green) method on a Cobas 6000 
auto analyzer (Roche Diagnostics, Mannheim, Germany; reference range 35-52 g/L). 
 Other biochemical parameters were determined using routine laboratory techniques. 
Blood samples were generally collected predialysis at midweek with the exception of the post 
dialysis serum urea for kinetic modeling.  
Calculation of normalized protein catabolic rate was based on the formula (13), nPCR= 
(0.136 × F) + 0.251. Where F = Kt/V × ([pre dialysis BUN + post dialysis BUN] ÷ 2).  
Statistical analysis 
Pearson’s or Fisher’s exact test was utilized for proportion comparisons. Continuous 
variables are presented as means± standard deviations or medians and inter quartile ranges 
(IQR) as appropriate.  Associations between serum alkaline phosphatase and other 
biochemical parameters were assessed by multiple linear regression analyses. Cox 
proportional model was used to determine the crude and adjusted hazard ratios of death for 
different categories of serum alkaline phosphatase, calcium, PTH, phosphate, 25 (OH) D and 
white versus black patients. Patients’ demographic and baseline characteristics were 
compared between the low and high total alkaline phophatase groups as well as white versus 
black patients, using an independent t – test and Mann- Whitney-U test for normally 
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distributed and non-normally distributed  variables respectively. One way ANOVA and 
Kruskal-Wallis tests were used to compare normally and non- normally distributed 
continuous variables across categories of serum calcium. 
 A P value of less 0.05 was considered statistically significant at the 95% confidence interval.  
All analyses were performed using STATA version 12 (STATA Corp., TX, and USA). 
 
4.3 Results 
The study included two hundred and thirteen patients (137 men, 76 women) undergoing 
MHD. The mean (±SD) of age, median dialysis vintage and mean Kt/V were 54.5±15.6 
years, 24 months (IQR, 12-48) and 1.44±0.3 respectively.  The majority of the patients were 
on three times weekly, 4 hr sessions of haemodialysis. Most of the patients were dialyzed 
with a dialysate calcium concentration of 1.50 mmol/L, which is usually modified based on 
serum levels of calcium. The blood and dialysis flow rates are generally 300-400mls/min and 
500 mls/min respectively. However, these values varied according to patient’s blood pressure 
and haemodynamic state.  A native arteriovenous fistula was used in more than half of the 
study population (60.6%). Almost all patients (93.0 %) were on erythropoiesis-stimulating 
agents (ESAs). 
Table 4.1 shows the comparisons of baseline clinical characteristics between patients in high 
TAP and low TAP groups. The low alkaline phosphatase group had significantly higher mean 
age than the high TAP group. Other parameters were comparable between the groups. For the 
management of CKD-MBD, 76.9 % of the patients were on calcium carbonate and 64.3% on 
alfacalcidol with a similar distribution of drug usage across the groups. The study population 
included 120 (56.3%) black and 93(43.7%) white patients. The mean age, hemoglobin 
concentration, albumin and phosphate were significantly higher in white compared to black 
patients.  Fifty six (26.3%) of the study population had diabetes and the proportion was 
higher in black patients (30.0% versus 21.5 %, P=0.02) (Table 4.2).  
The characteristics of the patients across different categories of serum calcium levels are 
shown in Table 4.3. Patients in the highest category of calcium levels had significantly lower 
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mean serum creatinine, and a fewer of them were on calcium carbonate and alfacalcidol. No 
significant differences were found in other parameters of the patients across the serum 
calcium categories. The overall mean dialysate calcium was 1.65±0.24 mmol/l and patients 
with higher levels of calcium are more likely to be dialyzed with lower dialysate calcium 
concentration. To further explore our practice pattern regarding treatment of hypecalcaemia, 
available data revealed that only 5 patients in the highest category of calcium had 
parathyroidectomy while the majority of them were dialyzed with 1.25 mmol/l of dialysate 
calcium concentration and had their calcium carbonate and alfacalcidol discontinued. 
During a follow up period of 7 years there were 57 (26.8%) deaths. After adjusting for 
cofounders such as age, other markers of bone disorder (calcium, phosphate, and PTH), 
serum alanine transaminase, 25 (OH) D and co-morbidity (diabetes mellitus), patients in the 
high TAP group had significantly higher risk of death compared to patients in the low TAP 
group (hazard ratio, 2.5; 95% CI 1.24-5.01, log rank P=0.01).  
Patients in the highest category of corrected calcium (>2.75 mmol/L) had more than a six 
fold increased risk of death compared to patients with normal calcium (HR 6.34, 95% CI 
1.40-28.76; P=0.02). Similarly, we found a significant association between race and 
mortality, in which white patients had an accentuated six fold increase in  adjusted hazard 
ratio for  death compared to black patients (HR 6.88,95% CI 1.82-25.88; P=0.004) (Table4). 
Figures 4.1, 4.2, and 4. 3 show Kaplan Meier Survival curves for TAP, race and calcium 
levels respectively. 
Univariate linear regression analysis revealed a significant association between TAP and age 
(r
2
 = 0.04, P=0.008), corrected calcium (r
2
=0.03, P=0.04), and PTH (r
2
=0.04, P=0.006). In 
multivariate regression analyses PTH and calcium remained significantly correlated with 
TAP, P=0.006 and 0.04 respectively. 
 
4.4 Discussion 
Several studies from Europe, America and Asia have consistently shown a linear relationship 
between high serum alkaline phosphate and   mortality in the haemodialysis population (14-
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17),  while results relating to other markers of mineral metabolism revealed  non- linear ( U 
or J patterns) associations (12, 18, 19).  Such data relating to the impact of markers of CKD-
MBD on mortality in African MHD patients are lacking. In this present study, higher levels 
of TAP, hypercalcaemia and white race were associated with increased risk of death. These 
findings are consistent with other large studies where higher levels of TAP were 
independently associated with higher risk of mortality (14, 17). 
Interestingly, this association was also reported in CKD patients as well as in the general 
population (20, 21). The National Health and Nutrition Examination Survey (NHANES) data  
revealed an independent association between elevated levels of TAP and mortality in the 
general population (21). This further supports the notion that TAP is more than a marker of 
high bone turnover and may be a reliable predictor of mortality.  
The mechanisms for this association have been linked to enhanced   vascular calcification by 
high levels of serum TAP through hydrolysis of pyrophosphate or activation of apatite crystal 
formation (22). In addition to vascular calcification, elevated levels of TAP have been 
associated with high C reactive protein, insulin resistance and 25 (OH) D deficie (23-26).  In 
contrast to our study, we found no significant difference in the mean levels of 25(OH) D 
between patients with high TAP and low TAP.   
Despite the variations in the cut-off points for defining hypercalcaemia by various studies, 
hypercalcaemia has been consistently associated with increased risk for mortality in 
haemodialysis patients (12, 18, 27). Consistent with our finding, a linear relationship was 
observed between higher calcium categories and increased risk of death (12, 18).  In a large 
global  representation of HD patients including the three phases of  the dialysis  outcomes and 
practice patterns study (DOPPSI,II and III)  with 25,588 HD patients, calcium levels greater 
than 10.0 mg/dl (>2.5mmol/l) were significantly  associated with greater risk of  all cause and 
cardiovascular mortality in both baseline and time dependent models (27). The reasons for 
this consistent association could be linked to acceleration of arterial calcification by 
hypercalcaemia (28, 29). Besides vascular calcification, high levels of calcium, but not high 
PTH have been associated with poor mental health in MHD patients (30).  In contrast, studies 
relating to hypocalcaemia and risk of death have yielded contradictory reports. Lowrie and 
Lew (31) were the first to establish the association of increased mortality with calcium levels 
<9.0 mg in over 12,000 HD patients, while in another large  study from the US involving 40, 
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538 HD patients, the mortality risk with low serum calcium levels  was attenuated after 
adjusting for confounding variables (18). In the dialysis outcomes and practice patterns study 
(32), serum calcium levels < 7.8 were associated with lower mortality risk. In agreement with 
DOPPS, we found a similar trend, though not statistical significant, with serum calcium 
levels below 2.12 mmol/L.  
Hypercalcemia is an undesirable effect associated with the use of   calcium based phosphate 
binders and vitamin D analogues in controlling secondary hyperparathyroidism. This may 
likely have accounted for the lower levels of PTH seen in our category of patients with 
calcium levels above 2.75 mmol/L.  Although cinacalcet which is one of the   newer drugs 
that effectively lowers PTH without raising serum calcium levels recently became available 
in South Africa,  it is quite expensive, thus limiting its use to  a few of our patients. In 
addition, the higher mean phosphate level in this group of patients is likely due to the 
concomitant use of alfacalcidol that enhances intestinal absorption of calcium and phosphate. 
A notable finding in the current study is that white patients have poor survival compared to 
black patients. This finding is consistent with recent emerging data from the USA that 
reported better survival in black patients compared with white patients on MHD (10). The 
reasons underlying this racial survival benefit remain unclear, and several studies have 
proposed explanations for the better survival of black MHD patients compared to whites. A 
large USA  observational study  reported that  the widely perceived  survival advantage for 
black dialysis patients applies only to older adults,  with a reversal of the higher risk of  death 
in the younger age group (<50 years) (33). This is contrary to several studies including the 
current study, where the risk persisted after adjusting for the significantly higher mean age in 
the white patients (34, 35).  Indeed, the better survival in black patients persisted in a study 
that comprehensively adjusted   for demographics   and dialysis modality among several other 
cofounding variables (34).    
Another important observation we made in this study was that white patients had 
significantly higher levels of serum albumin. We expected this to give white patients a 
survival benefit. However, the reason for this reversal could likely be explained by a finding 
from a previous study where markers of  worse nutritional status (hypoalbuminemia), or 
smaller muscle mass and increased body fat  in African American patients correlated less 
strongly with mortality than in whites (36). Additionally, studies have criticized the use of 
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serum albumin in CKD   patients as a marker of nutritional status as inappropriate (37, 38). In 
fact, the hazard ratio becomes accentuated after adjusting for serum albumin suggesting that 
the effect of race on mortality is likely to be through other mechanisms besides nutritional 
status. 
In line with previous studies (33, 39), black patients had higher median intact PTH though 
this was not statistically significant. Some studies have reported survival benefit with active 
D therapy and that black patients are more likely to receive active vitamin agents due to 
higher PTH compared to white patients (40, 41).  However, it is unlikely that treatment with 
vitamin D alone may explain the racial survival paradox that has existed for several years.  
Additionally, reports relating to PTH levels have been controversial and studies are divided 
on which levels are associated with increased mortality. Similar to earlier (17, 18, 42) and 
more recent studies (10, 43), we did not find significant association of mortality with severe 
hyperparathyroidism. On the other hand, studies that have shown significant associations are 
not unified on what levels of PTH are associated with increased mortality. Therefore, 
randomized control trials are needed to show the effect of treatment on PTH levels that are 
associated with favorable clinical outcomes.  
Our findings should be considered in the context of the following limitations. Firstly, the 
retrospective nature of this study could not allow us to make causal associations between 
markers of mineral bone disease and study outcome (death).  In addition, the use of a single 
baseline laboratory measurement precludes the performance of time dependent Cox analysis 
to account for variations in the biochemical markers on the impact of death over a period of 
time.  However, few studies have shown no significant difference between the baseline and 
time dependent Cox analysis (12). 
Secondly, the relatively small sample size precludes generalizability of our findings to 
African HD patients. Thus, there is a need for multicenter studies in Africa, to provide robust 
data on this important clinical entity (CKD-MBD) in African HD patients. 
Thirdly, similar to several observational studies we could not account for residual 
confounding variables. For instance, aside from diabetes mellitus, other co morbid conditions 
could not be ascertained.  However, part of the exclusion criteria was to avoid patients with 
some co-existing conditions that are known as potential confounders.   
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The strengths of this study lie in the heterogeneous nature of our study population (black and 
white patients) in an African setting which  has allowed comparisons of data not only for 
Black Africans with Black Americans, but also between whites in Africa and USA/Europe. 
To our knowledge, this the first study in sub Saharan Africa that has given important insights 
regarding   the impact of alkaline phosphatase, calcium and race on mortality in African 
MHD patients. 
In summary, high TAP, hypercalcaemia and white race are associated with increased risk of 
death in MHD patients, thus, reaffirming the need to pay more attention to the two modifiable 
risk factors (calcium and TAP) in the management of CKD-MBD. 
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Table 4. 1: Comparisons of baseline characteristics between patients in high TAP and 
low TAP groups 
Characteristic All(N=213) TAP≤112(n=98) TAP>112(n=115) P value 
Age(years) 54.53±15.62 57.3±15.5 51.1±15.1 0.008 
Female, n (%) 76(35.7%) 35(35.7%) 41(35.7%) 0.25 
Diabetes, n (%) 56(26.3%) 27(27.6%) 29(25.2%) 0.76 
Weight (Kg) 71±9.6 70±9.5 69±9.6 0.53 
BMI (Kg/m
2 
) 24.7±0.9 24.9±1.0 24.5±1.6 0.83 
Dialysis vintage (months) 24(12-48) 36(12-60) 36(12-48) 0.55 
Systolic BP(mmHg) 134±21.8 135.5±19.6 133.5±24.4 0.38 
Diastolic BP (mmHg) 72.0±13.73 70.7±12.0 74.1±13.8 0.86 
Haemoglobin(g/dl) 10.3±2.0 10.2±1.9 9.9±2.1 0.10 
Potassium(mmol/l) 4.62±0.8 4.6±0.9 4.6±0.8 0.55 
Calcium (mmol/l) 2.25±0.14 2.32±0.30 2.34±0.29 0.58 
Corrected calcium(mmol/l) 2.40 ±0.25 2.50±0.22 2.50±0.21 0.42 
iPTH(pg/ml) 307(148-656) 246(137-527) 325(152-693) 0.09 
Phosphate(mmol/l) 1.59±0.6 1.60±0.6 1.40±0.6 0.07 
25-OH vitamin D(ng/ml) 21.16±10.71 20.4±8.8 22.2±12.9 0.83 
Alkaline phosphatase(U/L) 112(74-163) 74(62-96) 163(130-223) <0.001 
Albumin(g/L)  31.9±6.0 32.6±5.4 30.3±6.5 0.98 
Type of vascular access      
Arteriovenous fistula 129 (60.6%) 65 (66.3%) 64 (55.7%) 0.23 
Graft                                              39 (18.3%) 23 (23.5%) 26 (22.6%) 0.88 
Catheter 45 (21.1%) 21(21.4%) 24(20.9%) 0.97 
Alanine transaminase (U/L) 21.1±8.9 17.6±8.7 22.9±8.8 0.20 
Kt/V 1.44±0.28 1.4±0.3 1.4±0.2 0.72 
 n PCR (g/kg/day) 1.10±0.24 1.02±0.30 1.08±0.27 0.56 
T.cholesterol (mmol/l) 4.18±0.91 4.3±0.9 4.1±0.9 0.14 
 Medications     
Calcium carbonate, n(%) 163(76.5%) 77(78.6%) 86(74.7%) 0.74 
Alfacalcidol, n (%) 137(64.3%) 61(62.2%) 76(66.1%) 0.55 
ESA n (%) 198 (93.0%)  94(95.9) 104 (90.4%) 0.50 
ESA dose (U/week)  13373±4205 13714±4768 12957±3457 0.53 
Continuous variables are presented as means± standard deviations or median (interquartile range) and categorical data as 
frequencies(percentages) , BP= blood pressure , i PTH= intact parathyroid hormone, TAP= total alkaline phosphatase., ESA=erythropoietin 
stimulating agent, n PCR= normalized protein catabolic rate, BMI= body mass index. 
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Table 4. 2: Baseline characteristics of study population by race 
Parameters All (n=213) Black (n=120) White (n=93) P value 
Age (years) 54.53±15.62 51.0±14.6 58.7±15.9 <0.001 
Haemoglobin (g/dl) 10.3±2.00 9.9±1.98 10.7±1.94 0.004 
Systolic Bp (mmHg) 134±21.8 130±20.3 139±22.8 0.98 
PTH (pg/ml) 307(148-656) 327(137-658) 290(149-618) 0.97 
Calcium (mmol/l) 2.28±0.22 2.26±0.22 2.30±0.21 0.94 
Phosphate (mmol/l) 1.59±0.56 1.49±0.57 1.71±0.53 0.004 
Albumin (g/l) 31.9±6.0 30.8±6.5 33.04±5.5 0.03 
25(OH) vitamin D 
D(ng/ml) 
21.16±10.71 20.57±9.79 21.80±11.67 0.77 
TAP (U/L) 112 (74-163) 110 (75-151) 115(71-164) 0.33 
T.cholesterol (mmol/l) 4.2±0.8 4.0±0.9 4.1±0.9 0.05 
Diabetes, n (%) 56(26.3%) 36(30.0%) 20(21.5%) 0.02 
Male, n (%) 137(64.3%) 72(60.0%) 65(69.9%) 0.07 
Kt/V 1.44±0.3 1.41±0.3 1.46±0.30 0.40 
Continuous variables are presented as means± standard deviations or median (interquartile range) and categorical data as frequencies 
(percentages). BP= blood pressure, TAP=total alkaline phosphatase, PTH = parathyroid hormone 
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Table 4. 3: Patient characteristics by serum calcium categories 
Parameters <2.10mmol/l 
 (n=31) 
2.10-2.37mmol/l 
(n=92) 
2.38-2.75mmol/l  
(n=57) 
>2.75mmol/l 
(n=33) 
P-value 
Age (years) 50.9±15.0 52.9±15.0 58.3±16.4 56.5±26.1 0.09 
Systolic Bp  (mmHg) 130.9±18.6 138.8±21.5 139.8±30.7 138.9±21.5 0.18 
Diastolic Bp (mmHg) 71.2±15.3 71.7±11.2 76.4±18.9 71.2±11.1 0.38 
Haemoglobin (g/dl) 10.8±2.4 10.2±1.9 10.1±1.9 8.15±1.9 0.20 
Albumin g/L 32.0±5.2 32.7±6.0 30.5±6.6 29.5±5.0 0.26 
T.chol (mmol/l) 4.3±1.0 4.2±0.9 4.2±0.9 4.1±0.9 0.97 
25(OH) D ( ng/ml) 22.8±9.1 22.0±10.4 18.1±8.1 15.8±3.5 0.11 
PTH (pg/ml) 568.8±334.8 458.64±424.4 366.2±405.1 254.0±103.2 0.01 
Phosphate (mmol/l) 1.5±0.6 1.6±0.6 1.5±0.5 1.6±0.5 0.66 
Creatinine(µmol/l) 822.5±261.0 734.4±283.2 592.5±245.5 489.5±355.7 0.002 
Kt/V  1.4±0.2 1.5±0.3 1.4±0.3 1.4±0.4 0.33 
Vintage (months) 31.3±23.0 34.2±23.0 30.9±21.1 30.0±8.9 0.80 
Dialysate Ca (mmol/l) 1.65±0.24 1.63±0.14 1.63±0.14 1.54±0.24 0.50 
DM, n 13  15  17 11 0.40 
Medications      
Calcium carbonate n 
(%) 
30 (96.8%) 79(85.7%) 41(71.9%) 13(39.4%) <0.001 
Alfacalcidol n (%) 28 (90.3%) 63 (68.4%) 35 (61.4%) 11(33.3%) <0.001 
Continuous variables are presented as means± standard deviations or median (interquartile range) and categorical data as frequencies 
(percentages). BP= blood pressure, PTH= parathyroid hormone,  P values derived by one way ANOVA and  Kruskal –Wallis tests for 
continuous  variables and Chi squared for categorical variables. Serum categories based on KDOQI reference range.Ca= Calcium 
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Table 4. 4: Crude and adjusted hazard ratio (95%CI) of primary outcome by baseline 
characteristics 
Parameter Crude HR 95%CI P Adjusted 
HR 
95%CI P 
TAP >112 U/L 2.20 1.12-4.32 0.02 2.50 1.24-5.01 0.01 
Calcium (mmol/l)       
<2.10 0.66 0.32-1.35 0.26 0.97 0.22-4.26 0.97 
≥2.10-≤2.37 1.00 Reference     
>2.37-≤2.75 2.31 1.20-4.44 0.02 1.54 0.57-4.18 0.39 
>2.75 6.82 1.55-30.1 0.01 6.34 1.40-28.76 0.02 
PTH(pg/ml)       
<130 1.00 Reference     
≥130-≤585 1.26 0.57-2.79 0.56 2.77 0.61-12.58 0.19 
≥585 1.05 0.44-2.49 0.92 2.22 0.42-11.65 0.35 
Phosphate >1.50mmol/l 1.09 0.61-1.95 0.77 1.43 0.47-4.40 0.53 
25 OH vitamin D ≤30 
ng/ml 
2.21 0.66-7.35 0.19 1.07 0.23-4.79 0.92 
White race 1.69 0.95-3.04 0.08 6.88 1.82-25.88 0.004 
HR=hazard ratio, CI=confidence interval, TAP= total alkaline phosphate, PTH intact parathyroid hormone. Adjusted for  age, phosphate, 
calcium, PTH, TAP, diabetes, Systolic BP, 25-OH vitamin D, alanine transaminase and albumin, serum calcium categories based on 
KDOQI reference range . 
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Figure 4. 1: Kaplan Meier curve comparing patients in the high alkaline phosphatase to 
low alkaline phosphatase group 
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Figure 4. 2: Kaplan Meier survival curve between black and white 
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Figure 4. 3: Kaplan Meier survival curves for different categories of calcium  
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CHAPTER 5: MANUSCRIPT 3 
Racial variations in the markers of mineral bone disorders in chronic kidney 
disease patients in South Africa 
ABSTRACT 
Introduction 
Several studies have shown that serum intact parathyroid hormone (PTH), phosphate and 
vitamin D levels differ across races. These comparative studies were largely carried out 
between Caucasians and Black Americans. However, little is known of the existence of this 
association in an African chronic kidney disease (CKD) population.  
Patients and Methods 
A cross –sectional multicenter study involving two hundred and ninety three CKD patients 
from three renal units in Johannesburg, South Africa.  
Results 
The 293 CKD patients (208 blacks, 85 whites) had an overall mean age of 51.1±13.6 years, 
and black patients were significantly younger than the white patients (48.4 ±.13.6 versus 
57.1±15.5 years; p<0.001). Compared to whites, blacks had higher median intact PTH (498 
[37-1084] versus 274[131-595] pg/ml; p=0.03), alkaline phosphatase (122[89-192] versus 
103[74-144] U/L; p=0.03) and mean 25 OH vitamin D3 (26.8±12.7 versus 22.7 ±12.2 ng/ml, 
p=0.01) levels ,  while their median FGF23 (100 [34-639] versus 233[80-1370] pg/ml; 
p=0.002) and  mean serum phosphate (1.3±0.5 versus 1.5±0.5, p=0.001)  levels were 
significantly lower. In multivariable analyses, black race was independently associated with 
increased log PTH (β =0.488, p=0.01) and decreased   log FGF23(β=-0.636, p= 0.02). 
Similarly, blacks had a 3.08 times higher likelihood (95 % CI, 1.51-6.30, p =0.002) of 
developing severe hyperparathyroidism than whites.  
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Conclusion 
This study highlighted the existence of racial differences in the circulating markers of mineral 
bone disorders in an African CKD population. 
Keywords: Race, Fibroblast growth factor- 23, Chronic Kidney Disease, Mineral Bone 
Disorder. 
5.1 Introduction 
Modifiable abnormalities of markers of mineral bone disease (MBD) have been consistently 
associated with adverse clinical outcomes in patients with chronic kidney disease (CKD) (1-
3). Addressing these adverse outcomes has led to recommendations by various global and 
regional societies to assist physicians in the management of CKD-MBD (4-6). However, the 
consequences of these biochemical abnormalities have been shown to differ across different 
races and thus there is the need to establish race specific target values for these markers of 
MBD (7). For example, in the multi ethnic study of atherosclerosis (MESA) involving 6436 
participants, 25-hydroxyvitamin D (25-(OH) vitamin D) deficiency was associated with 
increased risk of coronary heart disease in white but not in black Americans (8). A similar 
trend was found in the National Health and Nutrition Examination Survey (NHANES III) ,  
where  low 25 (OH) vitamin  D was associated with a higher risk of all-cause mortality 
compared to  black  participants (9).  Furthermore, fibroblast growth factor (FGF) 23, which 
is now being considered as the principal mediator of secondary hyperparathyroidism has also 
been shown to differ across races (10, 11). In general, these comparative studies, largely from 
American populations reported  that compared to whites, blacks have lower levels of 25 (OH) 
vitamin D and FGF23 with higher parathyroid hormone (PTH) and alkaline phosphate levels, 
while results relating to phosphate levels are inconsistent (7, 10-12).  
The existence of these differences in a heterogeneous African CKD population is largely 
unknown. Therefore, the aim of this study was to examine   racial differences in the levels of 
FGF23 and traditional markers of mineral bone metabolism in a South African CKD 
population. 
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5.2 Materials and Methods 
This was a cross sectional multicenter study involving two hundred and ninety three CKD 
patients from three renal units in Johannesburg, South Africa.  Patients enrolled were aged ≥ 
18 years with established CKD. We excluded patients with active malignancy, acute kidney 
injury and a history of parathyroidectomy. In addition, we excluded patients of Indian and 
mixed race origin due to their negligible numbers. A structured questionnaire was used to 
obtain patients’ demographic characteristics, blood pressure measurements, co-morbid 
disease and medication history related to CKD-MBD. Determination of race was based on 
self-report by the participants. 
Laboratory measurements 
Plasma intact PTH was measured by an electrochemiluminescence immunoassay (ECLIA) 
run on a Cobas 6000 auto analyzer (Roche Diagnostics, Mannheim, Germany). 
FGF23 was measured using a sandwich based enzyme-linked immunosorbent assay kit from 
EMD Millipore Corporation (Billerica, MA, USA); assay lower limit of detection was 3.2 
pg/mL. Plasma 25(OH) D was measured using the high performance liquid chromatography 
(HPLC) kit (Recipe, Munich, Germany).  HPLC was used to selectively measure 25-(OH) D2 
and 25-(OH) D3 at a wave length of 264nm. The intra and inter assay coefficients of 
variation (CVs)   were < 5%.  Our institutional laboratory is a participating member in the 
vitamin D external quality assurance scheme (DEQAS). In this study, 25-(OH) D3 was used 
as a marker of vitamin D status to avoid confounding of the results from exogenous vitamin 
D supplementation. Serum calcium, phosphate and alkaline phosphatase were measured using 
the ADVIA 1800 centaur auto analyzer (Siemens Diagnostics, Tarrytown, USA).   
Creatinine was measured by a modified Jaffe reaction and glomerular filtration rate ( GFR) 
estimated using the four- variable Modified Diet Renal Disease (MDRD) equation (13): GFR 
(in mL/min per 1.73 m
2
) = 175 × SCr (exp[−1.154]) × Age (exp [−0.203]) × (0.742 if female) 
× (1.21 if black).  
Other biochemical parameters were determined as part of standard of care using routine 
laboratory techniques. 
87 
 
Operative definitions and laboratory reference values 
The reference ranges were 2.12- 2.50 mmol/l for calcium, 0.79-1.45 mmol/l for phosphate, 
53-128 U/L for total alkaline phosphatase and 10-65 pg/mL for intact PTH. 
25-(OH)vitamin D reference ranges: < 10 ng/mL  as severe deficiency, 10-29 ng/mL as  
moderate deficiency, 30-100 ng/ mL as sufficiency and > 100 ng/ mL as toxic.  
Based on the above reference values and KDIGO recommendations (5), hyperparathyroidism 
was defined as PTH> 130 pg/ml (2 times the upper limit of normal) and severe 
hyperparathyroidism as PTH > 585pg/ml (9 times the upper limit of normal). 
Hyperphosphataemia and hypocalcaemia were defined as serum phosphate > 1.45mmol/l and 
calcium < 2.12 mmol/l respectively.   
Ethical approval: All procedures performed in this study were in accordance with the ethical 
standards of the institutional research committee and with the 1964 Helsinki declaration and 
its later amendments or comparable ethical standards. The research protocol was approved by 
the Health Research and Ethics committee (HREC) of the University of the Witwatersrand; 
clearance certificate number M141016.  Written informed consent was obtained from each 
patient before enrolment into the study. 
Statistical analysis 
Continuous variables are presented as means± standard deviations or as medians and inter 
quartile ranges (IQR) as appropriate, while categorical data are reported as a percentage. An 
independent t-test or Wilcoxon rank -sum test compared continuous variables between blacks 
and whites while the Pearson’s or Fisher’s exact test was utilized for proportion comparisons.  
 PTH and FGF23 data were log transformed due to the skewed nature of these variables. 
Multiple linear regression models were employed to determine the effect of independent 
predictors on log transformed PTH and FGF23. 
Logistic regression analysis was used to determine the predictors of severity of 
hyperparathyroidism. Variables with p <0.10 on univariate analyses were eligible for 
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inclusion in the multivariate analysis. Spearman correlations were used to determine the 
correlation between FGF23, phosphate, PTH, 25-(OH) vitamin D3 and estimated GFR. 
A p-value of less 0.05 was considered statistically significant at the 95% confidence interval.  
All analyses were performed using STATA version 12 (STATA Corp., TX, and USA). 
5.3 Results 
Patient characteristics 
The 293 CKD patients comprised 208 black and 85 white patients with overall mean age of 
51.1±13.6 years. The clinical characteristics of the patients by race are summarized in table 5. 
1. Blacks were significantly younger, had higher blood pressure, median iPTH, alkaline 
phosphatase and mean 25 (OH) D3, but lower levels of median FGF23 and serum phosphate 
than white patients. Diabetes mellitus was significantly more prevalent in whites. The use of 
CKD-MBD related medications did not differ by race. 
Comparison of markers of CKD -MBD between black and white patients 
Racial variations in the levels of PTH, calcium, phosphate and 25-(OH) D3 according to 
stages of CKD are shown in Table 5.2. Median PTH and mean 25-(OH) D3 were 
significantly higher in blacks than whites in CKD stage 5. Blacks had higher levels of total 
alkaline phosphatase (TAP) than whites in stage 4 CKD. Median FGF23 and mean serum 
phosphate levels increased progressively across stages of CKD and became significantly 
higher in whites than blacks in CKD stage 5. 
Table 5.3 shows comparisons of markers of CKD-MBD between black and white patients 
with predialysis CKD and End stage renal disease.  In predialysis CKD patients, whites had 
significantly higher levels of FGF23 than blacks (55ng/ml [31-81] versus 32[22-57], p=0.01), 
and higher levels of calcium (2.33±0.11 versus 2.24±0.14, p=0.005). Other parameters were 
comparable between the two groups.  In patients with ESRD, levels of FGF23 and phosphate 
were significantly higher in whites than blacks (881[187-3634] versus (329[105-2557], 
p=0.03) and (1.70±0.48 versus 1.44±0.56, p=0.004) respectively.  Compared to whites, 
blacks had higher levels of PTH (758[360-1350] versus 358[179-814], p=0.0004) and 25-OH 
D (28.1±13.8 versus 22.0±12.2, p=0.004). 
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Comparisons between blacks and whites in the prevalence of abnormal levels of calcium, 
PTH, phosphate and 25-(OH) D3 across stages of CKD are shown in Figure 5.1, 5.2, 5.3 & 
5.4. The proportion of patients with hyperphosphataemia (72.7% versus 42.9 %; p<0.001) 
and vitamin D deficiency (76.7 % versus 57.5 %; p = 0.01) was higher in whites than blacks 
in CKD stage 5. The prevalence of abnormal levels of other markers of CKD-MBD was 
similar across the study populations. 
Associations between race, clinical characteristics and markers of CKD–MBD 
In line with a previous study (14), in a  multiple regression analysis adjusted for age, diabetes 
status, GFR, serum calcium, phosphate and alkaline phosphate levels; black race  remained 
significantly associated with increased log PTH(β =0.488, p=0.01) and decreased log FGF23 
(β=-0.636, p= 0.02); Table 5. 4. Similarly, we found a persistent significant association 
between log FGF23, calcium, phosphate and GFR. In an unadjusted univariate analysis, white 
race was significantly associated with decreased 25-(OH) D3; however, this was attenuated 
after adjusting for age, diabetes status, calcium and GFR. 
Further exploration of the association between FGF23 and other markers of CKD-MBD, 
showed FGF23 correlates positively with serum phosphate( r= 0.55, p < 0.001), and  PTH (r= 
0.40 p <0.001), and inversely with eGFR (r = -0.61, p < 0.001) (Figures 5.5 and 5. 6). 
Determinants of secondary hyperparathyroidism 
In logistic regression analysis, the independent predictors of severe hyperparathyroidism 
were black race (OR 3.08; 95% CI: 1.51-6.30, P=0.002) and GFR < 15 mls/min (OR 10.07; 
95 % CI: 4.70-21.56, P <0.0001). 
5.4 Discussion 
The racial disparities in markers of CKD-MBD have been documented in CKD populations 
in previous studies from America and Europe (14, 15).  A few studies from Africa have 
documented similar findings in healthy populations but not in CKD patients (16, 17). In this 
present study, with the exception of 25-(OH) vitamin D3 levels, our findings are consistent 
with those of previous studies (12, 14); we found that PTH and alkaline phosphatase are  
higher in black than white patients in CKD stage 5 and CKD stage 4 respectively. After 
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adjusting for the inconsistency between the two groups regarding diabetic status and age, 
black race still remained significantly associated with increased PTH.  Although the 
mechanisms behind these discrepancies remain largely unclear, several reasons proposed by 
prior studies included  racial differences in skeletal responsiveness to PTH levels, racial 
variations  in sensitivity to the phosphaturic effect of PTH and FGF23 , dietary intake of food 
rich in phosphate, and underlying genetic differences in bone mineral metabolism (14, 18, 
19).   
An interesting and unexpected finding was the significantly higher levels of 25(OH) D3  in 
CKD  stage 5 in blacks compared to whites; this was contrary  to most previous studies that 
reported lower levels of 25-(OH)vitamin D,  which was attributed  to skin pigmentation (14). 
It is anticipated that increased skin pigmentation in blacks will lead to decreased synthesis 
of25-(OH) vitamin D   from 7 dehydrocholesterol through exposure to sunlight. One of the 
limitations of our study was the non-availability of information relating to sun exposure 
which could have accounted for these differences; it is possible that our black patients with 
CKD stage 5 spent more time outdoors (outdoor occupations in a sunny climate) leading to 
more sun exposure compared to white patients. However, some studies have shown that 
blacks and whites have equal capacities to synthesize vitamin D  post exposure to repeated 
high doses of ultraviolet B light(20, 21).  Brazerol et al (21), comparing skin capacity for 
blacks and whites exposed to similar doses of ultraviolet B rays (280-315nm) twice a week 
for six weeks, reported similar response to vitamin D synthesis despite the fact that blacks 
had lower baseline 25 –OH D levels than the white participants.  A prior study from South 
Africa with the aim of assessing vascular calcification in haemodialysis patients found no 
difference in 25 (OH) vitamin D levels between black and white patients (22). In addition, the 
inconsistencies that exist in the relationship between vitamin D levels and clinical outcomes 
in blacks suggest that the mechanism behind the racial disparities is complex and multi-
factorial. For example, despite lower levels of 25-(OH) vitamin D demonstrated by some 
studies, blacks have lower rates of osteoporosis and bone fractures than age and gender 
matched white participants (23, 24).  
Studies relating to the prevalence of 25 (OH) D across stages of CKD revealed conflicting 
results. Consistent with prior studies, we found no association between vitamin D status and 
stages of CKD (12). In contrast to our study, the prevalence of 25 deficiency/insufficiency 
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rose slightly across the stages of CKD in the Nephro Test study (25). However, it is 
noteworthy that comparisons of vitamin D status across the studies are somewhat hampered 
by differences in the participants skin pigmentation, latitude, cut off values and assay 
methods employed between the studies. Additionally, it is suggested that vitamin D 
deficiency is more profound in diabetic patients likely due to heavy urinary loss of vitamin D 
binding protein (25, 26). Therefore, the higher prevalence of diabetes in our white 
participants could have accounted for the racial discrepancy in the levels of 25-(OH) vitamin 
D. This was further supported by the attenuation of the significant association between white 
race and 25-(OH)vitamin D3 after adjustment for diabetes status in the linear regression 
model with 25-(OH)vitamin D3 as the dependent variable. 
Consistent with previous studies, phosphate levels increase with worsening of kidney 
function and the increase was significantly higher in whites than blacks at CKD stage 5. It is 
possible that white patients are more likely to consume dairy products accounting for the 
higher phosphate levels; this could not to be ascertained in this study due to the non-
availability of dietary history. However, large studies from the US have reported that African 
Americans had lower consumption of dairy products than whites (27, 28).  However, 
understanding racial differences in serum phosphate levels is intriguing and other factors 
besides dietary phosphate need to be considered. For example, contrary to our findings some 
studies have shown surprisingly increased serum phosphate levels in blacks compared to 
whites despite increased levels of parathyroid hormone and thus attributing these differences 
to reduced urinary phosphate excretion and lower FGF23 in blacks (10, 11).  In line with 
these studies, our black patients had lower levels of FGF23 compared to whites. It is possible 
that higher phosphate levels in our white participants could have accounted for the 
differential levels in FGF23 as a compensatory mechanism.  Although this is contrary to the 
explanation offered by a prior study, that the lower levels of FGF23 in their black participants 
despite higher levels of phosphate could be as a result of decreased FGF23 expression(10). 
The complexity in racial disparities with phosphate and FGF23 levels is further compounded 
by variations in the use of phosphate binders and alfacalcidol.  In this study there are no 
differences between blacks and whites in the use of calcium carbonate and alfacalcidol.  
Consistent with previous studies (11, 29), FGF23 correlated positively with phosphate, PTH 
and inversely with GFR. The directions of these associations are physiologically plausible, 
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with FGF23 attempting to mitigate the effect of excess phosphate with worsening renal 
function. It is also noteworthy that significant positive association with white race persisted 
after adjusting for other confounding variables. In addition, the significant positive 
association with white race persisted after adjusting for other confounding variables. 
The limitations of our study included the cross-sectional study design; therefore we could not 
determine the longitudinal changes in markers of CKD-MBD, as well as seasonal variation in 
25 (OH) vitamin D levels. Information relating to UVB exposure and dietary phosphate are 
lacking. 
 The strengths of this study lie in the heterogeneous nature of our study population (black and 
white patients) in an African setting which  has allowed comparisons of data not only for 
Black Africans with Black Americans, but also between whites in Africa and USA/Europe.  
To our knowledge, few studies have compared FGF23 levels across races in developed 
countries and no such studies have been reported from Africa.  Therefore, this is the first 
study in Africa that has given important insights regarding the associations between FGF23, 
traditional markers of CKD-MBD and race in an African CKD population. Finally, in this 
study HPLC which is considered to be the gold standard for vitamin D measurement  (30)  
was used to specifically measure 25-(OH)vitamin D3 that is less affected by vitamin D 
supplementation. In addition, with the exception of HPLC several test methodologies were 
shown to demonstrate a considerable variation of individual 25-(OH) vitamin D values as 
compared with LC-MS/MS defined target concentrations (31).   
Conclusion. There was a racial difference in the markers of CKD-MBD; compared with 
whites, African blacks had higher levels of PTH, alkaline phosphatase and lower levels of 
FGF23 and serum phosphate. It remains unclear whether the present CKD-MBD 
management guidelines are appropriate for all races.  
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Table 5. 1: Characteristics of the study population 
Parameters All (n=293) Black (n=208) White(n=85) P 
Age(years) 51.1±13.6 48.4±13.6 57.9±15.5 P<0.001 
Gender n (%)     
Male 166 (56.7%) 114 (54.8%) 52 (61.2 %) 0.32 
Female 127 (43.3 %) 94 (45.2 %) 33(38.8 %) 
Systolic 
BP(mmHg) 
143±25 146±26 135±19 0.007 
Diastolic 
BP(mmHg) 
84±20 89±21 71±11 P<0.001 
Hb (g/dl) 11.3±2.4 11.3±2.5 11.4±2.2 0.83 
Albumin(g/dl) 37.0±7.0 37.0±6.9 37.0±6.7 0.55 
Calcium(mmol/l) 2.22±0.24 2.20±0.27 2.30±0.19 0.01 
iPTH (pg/ml) 353(133-914) 498(137-1084) 274(131-595) 0.03 
FGF23(pg/ml) 130(42-970) 100(34-639) 233(80-1370) 0.002 
Phosphate(mmol/l) 1.4±0.5 1.3±0.5 1.5±0.5 0.001 
TAP (U/L) 116(83-162) 122(89-192) 103(74-144) 0.03 
25-OHD (ng/ml) 25.6±12.7 26.8±12.7 22.7±12.2 0.01 
<30 ng/ml 191(91.8%) 128(61.5%) 63 (74.1%) 0.04 
<10ng/ml 18(6.1%) 8(3.8%) 10(11.8%) 0.01 
Causes of renal 
disease n(%) 
    
HTN  188(64.2%) 141(67.8%) 47(55.3%) 0.002 
DM  52(17.7%) 25 (12.0%) 27(31.8%) P<0.001 
ADPKD 11(3.8%) 5(2.4%) 6(7.1%) 0.06 
Obstructive 
uropathy 
6(2.0%) 3(1.4%) 3(3.5%) 0.50 
Unknown 36(12.3%) 34(16.3%) 2(2.4%) 0.05 
Medications     
Calcium carbonate 120(41.0%) 85(40.9%) 35(41.2%) 0.77 
Alfacalcidol 111(37.9%) 78(37.5%) 33(38.8%) 0.68 
Calcium carbonate 
(mg/day) 
3429±694 3375±678 3500±750 0.69 
Alfacalcidol (µg/ 
week) 
1.63±0.38 1.86±1.09 1.48±0.87 0.43 
Continuous variables are presented as means± standard deviations or median (interquartile range) and categorical data as frequencies 
(percentages), BP= blood pressure , i PTH= intact parathyroid hormone, TAP= total alkaline phosphatase, DM= diabetes mellitus, FGF = 
fibroblast growth factor , HTN=hypertension, ADPKD=autosomal dominant polycystic kidney disease 
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Table 5. 2: Markers of mineral bone metabolism by race and stages of CKD 
 Variable                 CKD stage 3 P                CKD stage 4 P                        CKD stage 5 P 
 Black(n=34) White(n=11)  Black(n=40) White(n=14)  Black(n=134) White(n=60)  
IPTH(pg/ml) 120(92-218) 86(76-166) 0.21 193(73-373 228(175-329) 0.54 758(360-1350) 358(179-814) 0.0004 
FGF23(pg/ml) 30(22-44) 42(31-134) 0.07 35(22-64) 63(34-81) 0.07 329(105-2557) 881(187-3634) 0.03 
Calcium(mmol/l) 2.25±0.15 2.31±0.10 0.22 2.23±0.15 2.34±0.13 0.009 2.18±0.31 2.26±0.21 0.08 
Phos (mmol/l) 1.04±0.23 1.05±0.14 0.75 1.13±0.25 1.27 0.10 1.44±0.56 1.70±0.48 0.004 
25-OHD3 (ng/ml) 24.3±9.3 24.7±11.9 0.91 24.6±11.1 24.3±12.80 0.94 28.1±13.8 22.0±12.2 0.004 
TAP (U/L) 98(77-138) 102(78-123) 0.76 114(97-166) 88(74-111) 0.03 123(88-209) 128(73-226) 0.14 
Continuous variables are presented as means± standard deviations or median (interquartile range) and categorical data as frequencies (percentages) ,  IPTH = intact parathyroid hormone , FGF = fibroblast growth factor  
, i PTH= intact parathyroid hormone, TAP= total alkaline phosphatase, Phos= phosphate 
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Table 5. 3: Markers of CKD-MBD by race in pre dialysis and ESKD 
Variable                        Pre dialysis     P   End Stage Kidney  Disease P 
 Black (n=74) White (n=25)  Black (n=134) White(n=60)  
iPTH(pg/ml) 160(84-280) 174(94-253) 0.81 758 (360-1350) 358 (179-814) 0.0004 
FGF23 (pg/ml) 32(22-57) 55(31-81) 0.01 329(105-2557) 881(187-3634) 0.03 
Calcium(mmol/l) 2.24±0.14 2.33±0.11 0.005 2.18±0.31 2.26±0.21 0.08 
Phos (mmol/l) 1.09±0.24 1.18±0.27 0.12 1.44±0.56 1.70±0.48 0.004 
25-OHD3 (ng/ml) 24.4±10.3 24.5±12.1 0.99 28.1±13.8 22.0±12.2 0.004 
TAP (U/L) 111(89-141) 74(74-114) 0.09 123(88-209) 128(73-226) 0.14 
GFR(mls/min /1.73m
2
) 30.9±12.7 30.1±12.5 0.77 N/A N/A  
Kt/V N/A N/A  1.41±0.30 1.46±0.30 0.40 
Continuous variables are presented as means± standard deviations or median(interquartile range) and categorical data as frequencies(percentages) , BP= blood pressure , i PTH= intact parathyroid hormone, TAP= total 
alkaline phosphatase,, FGF = fibroblast growth factor, GFR= Glomerular filtration rate, N/A= not applicable 
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Table 5. 4: Multivariable analysis of determinant of PTH, FGF23 and 25-(OH) D3 
GFR= Glomerular filtration rate, PTH= Parathyroid hormone 
 
 
 
 
 
 
Dependent variable (Log PTH) βcoefficient P βCoefficient p 
Independent variable Unadjusted Adjusted 
Age -0.010 0.03 0.013 0.02 
Diabetes -0.390 0.02 -0.112 0.61 
Female gender 0.236 0.09 0.247 0.12 
Black race 0.413 0.007 0.488 0.01 
Calcium -1.248 <0.001 -1.038 0.001 
Phosphate 0.541 <0.001 0.179 0.26 
25-(OH) vitamin D3 -0.005 0.35 -0.002 0.77 
Alkaline phosphatase 0.002 <0.001 0.002 0.001 
GFR  -0.040 <0.001 -0.030 P<0.001 
     
Dependent variable(Log FGF23)     
Independent variable     
Age -0.033 <0.001 -0.013 0.26 
Diabetes -0.763 0.01 -0.318 0.31 
black race  -0.765 0.003 -0.636 0.02 
PTH 0.622 <0.001 0.171 0.09 
Calcium 0.921 0.05 1.239 0.004 
Phosphate 2.077 <0.001 1.041 <0.001 
25-(OH) vitamin D3 0.019 0.04 0.009 0.31 
Alkaline phosphatase 0.002 0.02 0.001 0.20 
GFR  -1.329 <0.001 -0.752 P<0.001 
     
25 (OH)D (Dependent variable)     
Independent variable     
Age -0.215 <0.001 -0.207 <0.001 
Diabetes -8.745 <0.001 -4.610 0.03 
white race  -4.063 0.01 -1.471 0.41 
Albumin 0.385 0.001 0.267 0.02 
Calcium 9.214 0.002 11.461 <0.001 
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Table5. 5: Predictors of severe hyperparathyroidism (PTH>585 ng/ml) 
Variable OR 95% (CI) p 
Age < 65 years 0.77 0.32-1.84 0.56 
Black race  3.08 1.51-6.30) 0.002 
Diabetes 0.57 0.25-1.31 0.19 
25 (OH) D (<30ng/ml) 1.68 0.90-3.13 0.10 
GFR<15mls/min 10.07 4.70-21.56 P<0.001 
Female gender 0.82 0.47-1.43 0.48 
Hyperphosphataemia(>1.45mmol/l) 1.39 0.75-2.58 0.29 
Hypocalcaemia(<2.10mmol/l 1.46 0.74-2.92 0.28 
GFR= Glomerular filtration rate 
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Figure 5. 1: Prevalence of 25 (OH) D3 deficiency by race and stages of CKD 
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Figure 5. 2: Prevalence of hyperphosphataemia by race and stages of CKD. 
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Figure 5. 3: Prevalence of hyperparathyroidism  by race and stages of CKD 
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Figure 5. 4: Prevalence of hypocalcaemia by race and stages of CKD. 
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Figure 5. 5: Correlation between Log FGF23 and Phosphate 
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Figure 5. 6: Correlation between Log FGF23 and GFR 
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CHAPTER 6: MANUSCRIPT 4 
Influence of vitamin D receptor polymorphisms on biochemical markers of 
mineral bone disorders in South African patients with chronic kidney disease. 
ABSTRACT 
Background 
It remains unclear whether genetic factors may explain the reported variation in the levels of 
biochemical markers of chronic kidney disease mineral and bone disorders (CKD-MBD) 
across ethnic groups. Therefore, the aim of this study was to examine the influence of VDR 
polymorphisms on secondary hyperparathyroidism and its association with vitamin D levels 
in black and white South African study participants.  
Patients and Methods  
This was a cross sectional study involving 272 CKD stage 3- 5D patients and 90 healthy 
controls. The four major VDR polymorphisms (Bsm 1, Fok 1, Apa1, and Taq 1) were 
genotyped using the polymerase chain reaction- restriction fragment length polymorphism 
(PCR –RFLP) method. In addition, the biochemical markers of CKD-MBD were measured to 
determine their associations with the four VDR polymorphisms.   
Results 
With the exception of Taq I polymorphism, the distribution of the VDR polymorphisms 
differed significantly between blacks and whites. In hemodialysis patients, the Bb genotype 
was significantly associated with moderate secondary hyperparathyroidism (OR, 3.88; 95 CI 
1.13-13.25, p=0.03) and severe hyperparathyroidism (OR, 2.54; 95 CI 1.08-5.96, p=0.03). 
This was consistent with the observed higher levels of median PTH and mean phosphate in 
patients with Bb genotype. This candidate risk genotype (Bb) was over represented in blacks 
compared to whites (71.0 % versus 55.6 %, p <0.0001).  In an unadjusted regression model, 
FokI Ff genotype was found to be significantly  associated with the risk of developing severe 
vitamin D deficiency < 15ng/ml  (OR, 1.89; 95 CI 1.17-3.07, p=0.01 ).  
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Conclusion.  
The VDR Bb genotype is an independent predictor of developing secondary 
hyperparathyroidism in patients with end stage kidney disease. In addition, study participants 
with the FokI Ff genotype are at increased of developing severe 25(OH) D deficiency 
6.1 Introduction 
Vitamin D deficiency has been linked to various disease conditions and poor clinical 
outcomes (1-3). The widespread consequences of   vitamin D deficiency have been partly 
attributed to the ubiquitous distribution of the vitamin D receptor (4).  The vitamin D receptor 
(VDR) plays a vital role in mediating the effects of the biologically active form of vitamin D 
(1, 25, OH-D); therefore it is plausible that variations in these receptors will modulate the 
consequences associated with vitamin D deficiency (5).  In 1994, Morrison et al. (6) were the 
first to report an association between VDR polymorphisms and bone metabolism, showing 
that the common allelic variants in the VDR encoding genes can predict differences in bone 
density in healthy individuals (6). Subsequently, several researchers have explored this 
relationship in CKD populations with emphasis on the calcium/ PTH/ calcitriol axis (7, 8). 
The  BsmI polymorphism (BB genotype) has been associated with slower progression of 
secondary hyperparathyroidism and normal levels of calcitriol in pre dialysis CKD patients, 
and lower levels of parathyroid hormone (PTH) in hemodialysis, and a greater reduction in 
PTH levels in response to a single bolus of calcitriol therapy compared   to patients with the 
bb genotype (8, 9).  However, contrary to earlier studies, findings from subsequent studies on 
the associations between VDR polymorphisms and markers of mineral bone disease have 
been inconsistent.  For instance, some studies reported no difference in PTH levels between 
the various Bsm I genotypes (10, 11), while Chudek et al. reported significantly lower levels 
of calcitriol in patients with BB genotype (12). Similarly, some studies have linked other 
VDR polymorphisms to mineral bone metabolism in hemodialysis patients. The VDR Fok I 
polymorphism (FF genotype) was reported to be associated with higher PTH levels (13).  
Furthermore, the existence of racial disparities in abnormal markers of CKD-MBD and the 
better survival paradox in African Americans compared to white dialysis patients may be 
explained partly by the racial differences in the distribution of VDR polymorphisms and 
VDR receptor activation therapy.  Most of these studies were conducted on European, Asian 
and American CKD populations, while studies from Africa were largely on non CKD 
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populations. Therefore, in line with ongoing efforts to greater understanding of the 
mechanisms behind racial disparities in markers of CKD-MBD, we aimed to explore the 
variations in the VDR polymorphisms between black and white African CKD patients and 
their relationship with markers of mineral bone disorders.  
 
6.2 Patients and Methods 
This was a cross- sectional study involving 272 CKD stage 3- 5D patients and 90 healthy 
controls. The study protocol was approved by the Health Research and Ethics committee 
(HREC) of the University of the Witwatersrand; clearance certificate number M141016. All 
participants gave written informed consent prior to enrolment. Exclusion criteria included 
active malignancies, aged < 18 years, and patients who withheld consent. Information on 
participants’ demographic characteristics, duration on dialysis and use of medications related 
to CKD-MBD were obtained. Determination of race was based on self-reporting by the 
participants.  
Laboratory measurements 
Plasma intact PTH was measured by an electrochemiluminescence immunoassay (ECLIA) 
run on a Cobas 6000 auto analyzer (Roche Diagnostics, Mannheim, Germany). 
FGF-23 was measured using an enzyme-linked immunosorbent assay kit from EMD 
Millipore Corporation (Billerica, MA, USA). Assay lower detect limit was 3.2 pg/ml.  Plasma 
25(OH) D was measured using the high performance liquid chromatography (HPLC) kit 
(Recipe, Munich, Germany). HPLC was used to selectively measure 25(OH) D2 and 25 (OH) 
D3 at a wave length of 264nm. The intra and inter assay coefficients of variation (CVs)   were 
< 5%.  Our institutional laboratory is a participating member in the vitamin D external quality 
assurance scheme (DEQAS). In this study, 25 (OH) D3 was used as a marker of vitamin D 
status to avoid confounding of our results by exogenous vitamin D supplementations.  Serum 
calcium, phosphate and alkaline phosphatase were measured using the ADVIA 1800 centaur 
auto analyzer (Siemens Diagnostics, Tarrytown, USA).  
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Creatinine was measured by a modified Jaffe reaction and  GFR was estimated using the 
four- variable Modified Diet Renal Disease (MDRD) equation (14): GFR (in mL/min per 
1.73 m
2
) = 175 × SCr (exp[−1.154]) × Age (exp[−0.203]) × (0.742 if female) × (1.21 if 
Other biochemical parameters were determined using routine laboratory techniques. 
Genotyping 
DNA was extracted from whole blood using the Maxwell DNA purification kit (Promega 
AS1010, USA). Using appropriate primers  and 50 ng of  DNA polymerase chain reaction 
(PCR)  products were amplified  for ApaI (Forward: 5’CAGAGCATGGACAGGGAGCAAG 
3’ and Reverse: 5’ GCAACTCCTCATGGCTGAGGTCTCA 3’ with 65 0C as annealing 
temperature), BsmI  (Forward : 5’ CAACCAAGACTACAAGTACCGCGTCAGTGA 3’ and 
Reverse: 5’ AACCAGCGGGAAGAGGTCAAGGG 3 ‘  with 65 0C as annealing 
temperature),  FokI ( Forward: 5’ AGCTGGCCCTGGCACTGACTCTTGCTCT 3’ and 
Reverse:  5’ ATGGAAACACCTTGCTTCTTCTCCCTC 3’ with 67 0C annealing 
temperature), and TaqI ( Forward:5’CAGAGCATGGACAGGGAGCAAG3’ and Reverse 
:5’GCAACTCCTCATGGCTGAGGTCTCA 3’ at an annealing temperature  of 65 0C )  VDR 
polymorphisms. The PCR products were then digested with enzymes ApaI, BsmI, FokI, and 
TaqI (New England Biolabs, Beverly, MA, USA) according to the supplier’s protocol. 
Digestions for   BsmI and TaqI were at 65 
0
C overnight, and 3hrs at 25 
0
C for ApaI, while 
FokI  was incubated at  37 
0
C for 3 hrs.  Restricted products were electrophoresed on either 
10% polyacrylamide or 1.5% agarose gels and then visualized by the Gel Doc TM EZ imager 
(Bio-Rad systems, USA). Genotypes were scored based on the presence or absence of a 
restriction site for the enzymes BsmI, ApaI, and TaqI at the 3′ untranslated region and FokI at 
the N-terminal region of the gene. 
Statistical analysis  
The Fisher’s exact test was utilized to compare differences in the frequency of genotypic 
distribution between groups. Based on the distribution of data, an independent t– test or 
Wilcoxon rank –sum test were used to compare continuous variables between two groups, 
while one- way ANOVA or Kruskal –Wallis tests were used for more than two groups. Both 
univariate and multivariable logistic regression models were used to determine the 
association between VDR genotypes, secondary hyperparathyroidism and vitamin D 
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deficiency. In the comparisons of the means and medians of the  circulating markers of CKD-
MBD across the genotypes, the P values for distribution between homozygous dominant and 
heterozygous genotypes were further  determined separately due to the smaller numbers of 
the homozygous  recessive. A backward selection procedure was used to fit the multiple 
regression model, which started with all potential predictor variables and subsequently 
removed the variables that had p values above the specified P=0.20.However, variables that 
are known to be biologically plausibly associated with secondary hyperparathyroidism were 
forced into the model despite not meeting inclusion criteria based on the stepwise approach. 
A post estimation test for Goodness of Fit of the models was carried out using Hosmer -
Lemeshow goodness of fit test. 
A p-value of less 0.05 was considered statistically significant at the 95% confidence interval.  
All analyses were performed using STATA version 12 (STATA Corp., TX, and USA). 
6.3 Results  
Description of the study population. 
A total of 362 participants (272 CKD patients and 90 controls) were recruited for this study. 
The CKD group comprised of 156 CKD stage 5D and 116 CKD stages 3-5 patients.  In the 
control group, 39 participants were self-identified as Whites, 60 as Blacks, and one Indian.  
The CKD group comprised of 73 Whites, 175 Blacks and 21 Indians. Fifteen patients were 
excluded from the genetic analysis due to failed genotyping (Figure1). Patients on 
haemodialysis were on three times weekly, 4 hr sessions of  haemodialysis using 
polysulphone membranes and bicarbonate dialysate. Most of the patients were dialyzed with 
a dialysate calcium concentration of 1.50 mmol/L, which is usually modified based on serum 
levels of calcium. The blood and dialysis flow rates are generally 300–400 mls/min and 
500 mls/min, 
Table 6.1 shows the ethnic distribution of the VDR polymorphisms (Bsm I, FokI, ApaI and 
Taq I). In the VDR polymorphisms, blacks had significantly higher proportion of Bb 
genotype than whites (71.0 % versus 55.6 %), and lower frequency of BB genotype (24.1 % 
versus 44.4 %). Overall, the most common genotype was Bb (65.4%). Similarly, the 
distribution of Fok I and Taq I genotypes differed significantly between the groups; FF was 
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more frequent in blacks, while the Ff genotype was the most prevalent in whites. There was 
no significant ethnic variation in the distribution of the ApaI genotype. 
Table 6.2 shows the distribution of the four VDR polymorphisms (Bsm I, FokI, ApaI and Taq 
I) between CKD patients and healthy controls, and the odds ratio of developing severe 
25(OH) D severe deficiency (< 15ng/ml). The frequencies of these genotypes did not differ 
significantly between the CKD and control groups. Ff genotype showed a significant increase 
in odds of developing severe 25 (OH) D deficiency (OR, 1.89; 95 CI 1.17-3.07, P=0.01); a 
similar trend was found with combined Ff + ff genotypes (OR, 1.91; 95 CI 1.18-3.08, 
P=0.008). The remaining genotypes were not significantly associated with severe 25(OH) D 
deficiency. 
The biochemical markers of CKD-MBD in the various genotypes are shown in Table 6.3.  
Median PTH and mean phosphate levels were significantly higher in patients with Bb 
genotype. In a restricted comparison between homozygous dominant genotype and 
heterozygous genotype due to smaller numbers of homozygous recessive genotype, the P 
values did not change significantly.    
In a restricted analysis involving hemodialysis patients, the univariate and multivariate 
analyses for the odds of developing moderate and severe secondary hyperparathyroidism are 
shown in Table 6. 4 Moderate secondary hyperparathyroidism was defined as PTH >130 
pg/ml (2 times the upper limit of normal) and severe secondary hyperparathyroidism as PTH 
> 585 pg/ml (9 times the upper limit of normal).  After adjusting for  serum calcium, 
phosphate, fibroblast growth factor 23, and use of  alfacalcidol, the Bb genotype was a 
significant predictor of developing both moderate (OR,3.88; 95 CI 1.13-13.25, p=0.03) and 
severe hyperparathyroidism(OR, 2.54; 95 CI 1.08-5.96, p=0.03).  The use of alfacalcidol was 
not eligible for inclusion into the final model, but was forced into the model due to a 
biologically plausible association between secondary hyperparathyroidism and the use of 
alfacalcidol. The post estimation test shows no lack of fit with the final models (p>0.05). 
6.4 Discussion  
In an attempt to unravel the complexity behind the pathophysiologic mechanisms of CKD -
MBD, several investigators have looked at the relationship between VDR polymorphisms and 
the calcium/PTH/calcitriol axis with inconsistent findings (5, 12). In this present study, 
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consistent with some previous reports, we found a significant difference in PTH levels across 
Bsm I genotypes, patients with Bb genotype had a higher median PTH level compared to 
patients with BB and bb genotypes.  In addition, the Bb genotype was independently 
associated with the risk of developing moderate and severe secondary hyperparathyroidism in 
patients with ESKD. The influence of BsmI on parathyroid function was also observed in pre 
dialysis CKD and transplant patients. Marco et al. (15) reported a slower progression of 
secondary hyperparathyroidism in pre dialysis CKD patients with BB genotype, while Messa 
et al. (16) reported lower PTH levels in transplant patients with BB genotypes.  On the other 
hand, contrary to our findings, some studies have reported non-significant differences in PTH 
levels across Bsm I genotypes. However, it is noteworthy that the Bsm I genotype distribution 
varies greatly across ethnic groups, hampering comparisons of studies.  
The molecular mechanisms by which BsmI VDR polymorphisms influence 
hyperparathyroidism have been linked to presence of b alleles. Previous studies have reported 
a strong association between b alleles and decreased VDR gene transcription and/or m RNA 
stability, hence, affecting the regulatory actions of calcitriol on parathyroid glands (6, 16). 
For example, patients with the BB genotypes are less susceptible to having reduced 1α-
hydroxylase levels compared to patients with bb genotypes. Therefore, patients with b alleles 
are less likely to have optimal levels of calcitriol required to inhibit PTH secretion and 
parathyroid cell proliferation. 
A few studies have also investigated the associations between FokI, ApaI and secondary 
hyperparathyroidism in patients with CKD.  Consistent with a prior study (13), although not 
statistically significant, patients with FF genotype had lower levels of PTH than patients with 
Ff in our study.   
In addition to the complexity of CKD -MBD is the existence of the ethnic variability in the 
development and severity of secondary hyperparathyroidism among CKD patients. Several 
previous studies consistently showed that black patients have higher PTH levels and lower 25 
(OH) D levels (17, 18). The mechanisms behind these dissimilarities may partly be explained 
by genetic factors. For example, some polymorphisms may be over represented in certain 
races and therefore alter their risk.  In this present study, there was a statistically significant 
difference between black and white participants in the   distribution of the VDR 
polymorphisms. The Bb genotype which is an independent predictor of hyperparathyroidism 
is over represented in black populations (71.0% versus 56.4 %, p<0.0001).  In line with our 
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findings, previous studies have also reported ethnic variations in the distribution of VDR 
polymorphisms (19, 20). Uitterlinden et al. (20) reported that the frequency of the f allele of 
Fok1 was lower in Africans as compared to Caucasians (Caucasians 34% versus Africans 
24%); similarly  a significant  difference was found in  the frequency of the Bsm1,  B allele 
was  lower in the Asian population compared to other populations (Asians 7 %, Africans 
36%, and 42 % in Caucasians). These observed ethnic variations in the frequency of the VDR 
polymorphisms may help in explaining the racial discrepancy in the markers of CKD-MBD. 
Several studies have consistently associated vitamin D insufficiency to various skeletal and 
extra skeletal clinical end points, leading to a special interest in the determinants of vitamin D 
metabolites (20, 21).  Thus far, well-established determinants of 25(OH) D levels include 
dietary sources and sun exposure (21).  However, a genetic factor has been shown to play a 
vital role in the inter individual variation in circulating vitamin D levels.  For example, in the  
classical twin study, Hunter  et al. reported that  the calcium/PTH/calcitriol axis  is under 
strong genetic influence, accounting for 52% of calcium excretion, 74% of bone formation, 
58% of bone resorption, 60% of PTH, and  65% of vitamin D variance (22).  Similarly, a 
more recent large GWAS study has revealed a significant association with some genetic 
variants with 25(OH) D levels (21). These important findings were restricted to Caucasians, 
limiting their results to other ethnic groups. However, a few studies that explored these 
associations across races yielded similar results (23). In agreement with these studies, we 
found an increased risk of developing severe vitamin D deficiency with FokI Ff genotype and 
combined Ff+ff genotypes. In contrast, we did not find a significant difference in vitamin D 
levels across the various VDR genotypes.  
The limitations of our study include the following:  Firstly, the influence of some wild type 
genotype (homozygous minor) on the calcium/PTH/calcitriol axis could not be adequately 
determined due to their smaller numbers. Thus, a larger sample will be required to detect 
their associations with markers of CKD-MBD. Secondly, this was a cross-sectional study 
design; therefore we could not determine the longitudinal changes in markers of CKD-MBD, 
as well as seasonal variation in 25 (OH) D levels. Thirdly, information relating to UVB 
exposure and vitamin D dietary history are lacking. 
The strength of this study lies in the heterogeneous nature of our study population (black and 
white patients) in an African setting which has allowed comparisons of data not only for 
Black Africans with Black Americans, but also between whites in Africa and USA/Europe.  
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6.5 Conclusion  
We have demonstrated that both moderate and severe secondary hyperparathyroidism are 
predicted by BsmI Bb genotype, and the over expression of this genotype in black patients 
may partly explain the ethnic variations in the severity of secondary hyperparathyroidism in 
CKD population. In addition, the Fok I  Ff genotype might be an important determinant of an 
individual’s susceptibility to 25 (OH) D deficiency.  
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Figure 6. 1: Participant disposition and recruitment flow chart  
 
118 
 
Table 6. 1: Participants’ characteristics and genotype frequencies by race 
Parameters Black(n=224)      White(n=110)     P 
Age(years) 46.5±12.9 54.4±17.5  <0.0001 
Gender n (%)    
Male  111(49.6%) 60(54.5%) 0.74 
Female 113(50.4%) 50(45.5%) 
25(O H)D(ng/ml) 25.8±12.1 23.1±11.9  0.048 
PTH(pg/ml) 214(61-872) 112(30-364)  0.001 
Calcium (mmol/l) 2.22±0.25 2.29±0.18 0.06 
TAP(U/L) 120(88-190) 110(74-145) 0.14 
Phosphate (mmol/l) 1.29±0.47 1.48±0.49 0.003 
FGF23(ng/ml) 59(23-307) 80(28-521) 0.20 
VDR genotypes    
Bsm I    
BB 54(24.1%) 48(43.6%)  
P<0.0001 
Bb 159(71.0%) 62(56.4%) 
bb 11(4.9%) 0(0.00%) 
    
Fok I    
FF 151(67.4%) 38(34.6%)  
P<0.0001 
Ff 71(31.7%) 69(62.7%) 
ff 2(0.89%) 3(2.73%) 
    
Apa I    
AA 94(42.0%) 40(36.4%)  
0.61 
Aa 127(56.7%) 69(62.7%) 
aa 3(1.34%) 1(0.91%) 
    
Taq I    
TT 128(57.1%) 44(40.0%)  
0.01 
Tt 80(35.7%) 52(47.3%) 
tt 16(7.1%) 14(12.7%) 
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Table6. 2: Distribution of VDR polymorphisms among CKD and control groups and the 
odds ratios for developing severe 25 -hydroxyvitamin D severe deficiency (< 15ng/ml) 
VDR genotypes Controls  CKD  p
a
 OR (95%CI) P 
Bsm I N= 84 N=268    
BB 23(27.4%) 87(32.5%) 0.05 1.00(reference)  
Bb 55(65.5%) 176(65.7%)  0.85(0.51-1.42) 0.55 
bb 6(7.14%) 5(1.87%)  0.28(0.03-2.32) 0.24 
Dominant model      
BB 23(27.4%) 87(32.5%)    
Bb +bb 61(72.6%) 181(67.5%) 0.38 0.83(0.50-1.37) 0.46 
Fok I N=86 N=266    
FF 45(52.3%) 152(57.1%) 0.47 1.00(reference)  
Ff 39(45.4%) 111(41.7%)  1.89 (1.17-3.07) 0.01 
ff 2 (2.3%) 3 (1.1%)  2.52 (0.41-15.59) 0.32 
Dominant model      
FF 45(52.3%) 152(57.1%) 0.43 1.00 (reference)  
Ff+ ff 41(47.7%) 114(42.9%)  1.91(1.18-3.08) 0.008 
Apa I N=83 N=269    
AA 32(38.6%) 112(41.6%) 0.50 1.00(reference)  
Aa 51(61.4%) 152(56.5%)  1.44(0.88-2.37) 0.15 
aa 0(0.0%) 5(1.86%)  2.33(0.37-14.57) 0.37 
Dominant model      
AA 32(38.6%) 112(41.6%) 0.70 1.00(reference  
Aa +aa 51(61.4%) 157(59.0%)  1.46(0.89-2.40) 0.13 
Taq I N=84 N=268    
TT 37(44.1%) 146(54.5%) 0.05 1.00(reference)  
Tt 42(50.0%) 95(35.5%)  1.00(0.61-1.65) 0.99 
tt 5(6.0%) 27(10.1%)  0.76(0.31-1.87) 0.60 
Dominant model      
TT 37(44.1%) 146(54.5%) 0.06   
Tt +tt 47(56.0%) 122 (45.5%)  0.96(0.59-1.53) 0.85 
      
OR= odds ratio, CI= confidence interval, CKD= chronic kidney disease, Pa  value for comparison of genotype frequencies between control and CKD groups, VDR= vitamin 
D receptor. 
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Table 6. 3: Levels of markers of CKD-MBD across various VDR genotypes 
Variable                 Genotypes p P
c
 
Bsm I BB(n=87) Bb(n=176) bb(n=5)   
25(OH) D(ng/ml) 21(14-33) 25(16-34) 27(19-31) 0.30 0.14 
PTH(pg/ml) 231(111-593) 553(197-1230) 169(134-214) <0.001 <0.001 
Calcium (mmol/l) 2.20±0.75 2.21±0.64 2.20±0.10 0.99 0.98 
Phosphate(mmol/l) 1.27±0.49 1.43±0.49 1.0±0.33 0.002 0.01 
TAP(U/L) 121(83-153) 113(88-173) 80(57-141) 0.373 0.91 
Medications n (%)      
Calcium carbonate 37(42.5) 89(50.6) 2(40.0) 0.19 0.07 
Alfacalcidol 28(32.2) 80(45.5) 1(20.0) 0.09 0.047 
      
Fok I FF(n=152) Ff(n=111) ff(n=3)   
25(OH) D(ng/ml) 24(14-34) 22(14-33) 15(11-29) 0.31 0.30 
PTH(pg/ml) 327(121-975) 360(166-735) 61(28-94) 0.12 0.86 
Calcium (mmol/l) 2.21±0.61 2.19±0.76 2.17±0.27 0.97 0.83 
Phosphate(mmol/l) 1.35±0.51 1.38±0.48 1.61±0.51 0.64 0.64 
TAP(U/L) 123(91-160) 103(79-167) 258(69-312) 0.47 0.35 
Medications n (%)      
Calcium carbonate 65(42.8) 59(44.1) 1(33.3) 0.23 0.11 
Alfacalcidol 60(39.5) 45(40.5) 1(33.3) 0.91 0.74 
Taq I TT(n=146) Tt (n=95) tt (n=27)   
25(OH)D(ng/ml) 23(15-32) 25(16-36) 21(15-32) 0.31 0.23 
PTH(pg/ml) 363(174-926) 327(109-913) 672(121-
1314) 
0.24 0.17 
Calcium 2.21±0.61 2.17±0.82 2.36±0.31 0.47 0.71 
Phosphate(ng/ml) 1.31±0.45 1.38±0.56 1.52±0.47 0.13 0.36 
TAP(U/L) 110(82-154) 123(93-192) 121(75-167) 0.39 0.17 
Medications n (%)      
Calcium carbonate 61(41.8) 52(54.7) 14(51.9) 0.41 0.18 
Alfacalcidol 54(37.0) 43(45.3) 11(40.7) 0.50 0.24 
      
Apa I AA (n=112) Aa(n=152) aa (n=5)   
25 (OH)D(ng/ml) 24(17-37) 22(15-32) 19(15-28) 0.22  
PTH(pg/ml) 329(137-957) 383(99-814) 1889(1359-
1889) 
0.04 0.63 
Phosphate(mmol/l) 1.34±0.52 1.37±0.48 1.63±0.47 0.46 0.52 
Calcium(mmol/l) 2.22±0.66 2.19±0.68 2.41±0.16 0.79 0.76 
TAP(U/L) 123(82-190) 115(88-149 160(91-440) 0.51 0.91 
Medications n (%)      
Calcium carbonate 49(43.8) 74(48.7) 5(100.0) 0.04 0.23 
Alfacalcidol 41(36.6) 64(42.1) 4(80.0) 0.29 0.33 
Variables are presented as means± standard deviations or median(interquartile range), TAP= serum total alkaline phosphate, PTH= parathyroid hormone,25 (OH)D=25 
hydroxyvitamin D 3, pc  value: comparison between Homozygous dominant and heterozygous genotypes 
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Table 6. 4: Odds ratios for association between VDR polymorphisms and secondary 
hyperparathyroidism in haemodialysis patients 
Polymorphisms Crude OR 95%(CI) P Adjusted*OR  
95%(CI) 
P 
Moderate secondary hyperparathyroidism (PTH>130 ng/ml) 
Bsm I     
BB 1.00(reference)  1.00(reference)  
Bb 3.12 (1.11-8.83) 0.03 3.88(1.13-13.25) 0.03 
bb N/A N/A N/A  
     
FokI     
FF 1.00(reference)  1.00(reference)  
Ff 0.87(0.31-2.39) 0.78 0.65(0.20-2.10) 0.47 
ff N/A N/A N/A  
     
Taq I     
TT 1.00(reference)  1.00(reference)  
Tt 0.27(0.09-0.84) 0.02 0.43(0.12-1.52) 0.19 
tt 0.53(0.09-2.96) 0.47 0.76(0.11-5.19) 0.78 
     
Apa I     
AA 1.00(reference)  1.00(reference)  
Aa 0.42(0.13-1.36) 0.15 0.25(0.06-1.01) 0.052 
aa 0.28(0.3-3.14) 0.30 0.25(0.01-3.10) 0.25 
     
Severe hyperparathyroidism (PTH>585 pg/ml) 
Bsm I     
BB 1.00(reference)  1.00(reference)  
Bb 2.55(1.19-5.47) 0.02 2.54(1.08-5.96) 0.032 
bb N/A N/A N/A N/A 
     
Fok I     
FF 1.00(reference)  1.00(reference)  
Ff 0.42(0.21-0.82) 0.01 0.37(0.17-0.81) 0.01 
ff N/A N/A N/A  
     
Taq I     
TT 1.00(reference)  1.00(reference)  
Tt 0.64(0.31-1.32) 0.23 0.71(0.32-1.59) 0.41 
tt 1.37(0.44-4.24) 0.58 1.39(0.41-4.73) 0.39 
     
Apa I     
AA 1.00(reference)  1.00(reference)  
Aa 0.85(0.43-1.69) 0.65 0.74(0.35-1.57) 0.43 
aa 2.26(0.24-21.47) 0.48 2.84(0.27-30.22) 0.86 
OR= Odds ratio, CI= confidence interval,  N\A -= not applicable, *Adjusted Odd ratio= adjusted for Age, calcium,  phosphate, 25 hydroxyvitamin D 3, 
Fibroblast growth factor 23 and  use of alfacalcidol,  
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Figure 6. 2: Restriction Endonuclease digestion for FokI polymorphism 
 
 
Figure 6. 3: Restriction Endonuclease digestion for ApaI polymorphism 
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Figure 6. 4: Restriction Endonuclease digestion for Bsm I polymorphism 
 
 
 
Figure 6. 5: Restriction Endonuclease digestion for TaqI polymorphism 
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CHAPTER 7: DISCUSSION 
7.1 Introduction 
Although CKD-MBD has been extensively studied, surprisingly large gaps of knowledge still 
exist in this field of nephrology as highlighted by the KDIGO group in 2013(1).  
 In addition, the group agreed that further studies are needed to assist in updating some of the 
2009 KDIGO clinical practice guidelines on the diagnosis and treatment of CKD-MBD. 
Therefore, in line with the KDIGO recommendations, we have conducted this study to assist 
in bridging the gaps in knowledge in the field of CKD-MBD. 
This chapter highlights our relevant findings; followed by comparisons of our findings with 
the existing literature; recommendations and clinical implications; study limitations and 
conclusions. 
7.2 The summary of our main findings are as follows: 
7.2.1. Spectrum of CKD –MBD 
The prevalence of hyperparathyroidism (iPTH>150 pg/mL), hyperphosphataemia, 
hypocalcaemia and 25-OH vitamin D deficiency (<30 ng/mL) was 73.4%, 57.0%, 20.3% and 
80.7 % respectively in our MHD patients 
7.2.2. Association between markers of CKD -MBD and mortality 
 Patients with high TAP had significantly higher risk of death compared to patients with TAP 
<112 U/L (hazard ratio, 2.50; 95% CI 1.24–5.01, P = 0.01). Similarly, serum calcium 
>2.75 mmol/L was associated with increased risk of death compared to patients within levels 
of 2.10–2.37 mmol/L (HR 6.34, 95% CI 1.40–28.76; P = 0.02). The HR for death in white 
patients compared to black patients was 6.88; 95% CI 1.82–25.88; P = 0.004. 
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7.2.3. Racial variations in markers of CKD-MBD 
Our study highlighted the existence of racial differences in the circulating markers of mineral 
bone disorders in an African CKD population. Compared to whites, blacks had higher median 
intact PTH (498 [37-1084] versus 274[131-595] pg/ml; p=0.03), alkaline phosphatase 
(122[89-192] versus 103[74-144] U/L; p=0.03) and mean 25 OH vitamin D3 (26.8±12.7 
versus 22.7 ±12.2 ng/ml, p=0.01) levels, while their median FGF23 (100 [34-639] versus 
233[80-1370] pg/ml; p=0.002) and  mean serum phosphate (1.3±0.5 versus 1.5±0.5, p=0.001)  
levels were significantly lower 
 
7.2.4. VDR polymorphisms and its association with markers of CKD –MBD 
There was a significant difference in the distribution of VDR polymorphisms between black 
and white patients; blacks had significantly higher proportions of Bb genotype than whites 
(71.0 % versus 55.6 %), and lower frequency of BB genotype (24.1 % versus 44.4 %).  The 
VDR Bb genotype was significantly associated with moderate secondary 
hyperparathyroidism (OR, 0.3.12; 95 CI 1.11-8.83, p=0.03) and severe hyperparathyroidism 
(OR, 2.55; 95 CI 1.19-5.47, P=0.02). 
7.3 Comparisons with the existing literature 
In Africa, data on the prevalence of secondary hyperparathyroidism and vitamin D status in 
the CKD population is sparse and limited by small sample size. In our study, the prevalence 
of secondary hyperparathyroidism (iPTH >150pg/mL) in maintenance haemodialysis patients 
was 73.4%.  This high prevalence is consistent with previous studies from Africa (2, 3), 
despite utilizing different cut-off values. The strength of our study is the larger sample size 
compared to other previous studies from Africa, in addition to providing data on 25-(OH) 
vitamin D status in our patients. 
In spite of the geographical location with high levels of vitamin D from sunlight, the majority 
of our MHD patients had 25 - (OH) vitamin D insufficiency. Inadequate vitamin D status 
defined as 25 - (OH) vitamin D level < 30 ng/ml was found in 80.7% of our study population. 
Similarly studies from countries with abundant sunlight have reported high prevalence of 
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vitamin D deficiency in healthy children and adults (4, 5). In fact, vitamin D deficiency has 
been termed a global health problem affecting over 1 billion of the world’s population (6).  
The consequences of deranged markers of CKD-MBD have been documented by studies 
mainly from American and Europe with few or no data from Africa. In our study we have 
highlighted that high levels of alkaline phosphatase, hypercalcaemia and white race are 
associated with increased risk of mortality. Our finding of hypercalcaemia and increased 
mortality is consistent with the three phases of the dialysis outcomes and practice patterns 
study (DOPPSI, II and III) with 25,588 HD patients, which showed that calcium levels 
greater than 10.0 mg/dL (>2.5 mmol/L) were significantly associated with greater risk of all 
cause and cardiovascular mortality in both baseline and time dependent models(7). 
The reawakened interest in alkaline phosphatase, which is one of the pioneer markers of bone 
turnover, is due to emerging evidence that has consistently associated high levels of alkaline 
phosphatase with increased risk of mortality (8, 9). These studies have indicated that alkaline 
phosphatase is not just a marker of bone turnover but could also serve as a predictor of 
mortality. In line with previous studies, we have shown an association between high levels of 
alkaline phosphatase and mortality in South Africa MHD patients. The mechanisms for the 
association between high TAP and increased mortality have been linked to enhanced vascular 
calcification by high levels of serum TAP through hydrolysis of pyrophosphate or activation 
of apatite crystal formation (10). In addition to vascular calcification, elevated levels of TAP 
have been associated with high C reactive protein, insulin resistance, and 25-OH vitamin D 
deficiency   
Despite racial disparity in access to health care and associated poor predictors of adverse 
outcome with black race in the general population, several studies from the USA have shown 
that black patients on haemodialysis have better survival than whites MHD patients (11, 12). 
This is the first study in Africa to highlight the existence of this association in African MHD 
patients. The mechanisms behind this survival paradox remain unclear; however, several 
reasons have been reported by some studies.  For example, a large USA observational study  
involving 1,330,007 incident end-stage renal disease  reported that the widely perceived 
survival advantage for black dialysis patients applies only to older adults, with a reversal of 
the higher risk of death in the younger age group (<50 years) (13). This is contrary to several 
studies including the current study, where the risk persisted after adjusting for the 
significantly higher mean age in the white patients (11, 12). Another reported explanation 
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was that racial variations in markers of nutritional status and response to inflammation may 
account for the survival paradox in MHD patients (11, 12). For example, Streja et al. (11) 
reported that markers of worse nutritional status and increased body fat in African American 
patients correlated less strongly with mortality than in whites. Additionally, psychosocial and 
coping mechanisms with disease conditions may vary across race. 
In an attempt to reduce adverse clinical outcomes associated with CKD-MBD, guidelines 
were proposed by various global and regional societies to assist physicians in the 
management of CKD -MBD. However, biochemical markers of CKD-MBD have been 
shown to differ across different races and thus there is the need to establish race specific 
target values for these markers of CKD-MBD.  For example, in this present study, with the 
exception of 25-(OH) vitamin D3 levels, our findings which are consistent with those of 
previous studies, showed that PTH and alkaline phosphatase are higher in black than white 
patients in CKD stage 5 and CKD stage 4 respectively. The mechanisms behind this 
discrepancy remain largely unclear.  Therefore, in line with ongoing efforts to gain greater 
understanding of the mechanisms behind racial disparities in markers of CKD-MBD, we also 
explored the variations in VDR polymorphisms between black and white African CKD 
patients and its relationship with markers of mineral bone disorders.  The influence of genetic 
factors on the inter-individual variation in circulating markers of CKD-MBD was first 
reported by Hunter  et al.(12) who reported  that the calcium/PTH/calcitriol axis  is under 
strong genetic influence, accounting for 52% of calcium excretion, 74% of bone formation, 
58% of bone resorption, 60% of PTH, and  65% of vitamin D variance.  In our study, there 
was a statistically significant difference between black and white participants in the 
distribution of the VDR polymorphisms. The Bb genotype which is an independent predictor 
of hyperparathyroidism is overexpressed in the black populations (71.0% versus 56.4 %, 
p<0.0001).  In line with our findings, some previous studies have also reported ethnic 
variations in the distribution of VDR polymorphisms. Uitterlinden et al. (14) reported that the 
frequency of the f allele of Fok1 was lower in Africans as compared to Caucasians 
(Caucasians 34% versus Africans 24%); similarly,  a significant  difference was found in  the 
frequency of the Bsm1 B allele which was  lower in the Asian population compared to other 
populations (Asians  7 %, Africans 36%, and 42 % in Caucasians). Therefore, these observed 
ethnic variations in the frequency of the VDR polymorphism may help in explaining the 
racial discrepancy in the markers of CKD -MBD.   
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7.4 Clinical implications of our findings and recommendations 
Surprisingly, despite the strong association between abnormal markers of CKD-MBD, there 
is a paucity of data on the prevalence of secondary hyperparathyroidism in African MHD 
patients. Therefore, the findings from this study have provided us with important insights on 
the spectrum of CKD-MBD in African MHD patients. The highlighted high prevalence of 
secondary hyperparathyroidism and vitamin D deficiency in MHD patients has drawn our 
attention to the need to aggressively manage secondary hyperparathyroidism in our MHD 
patients. In addition, emphasis should be placed on mitigating the wider effects of vitamin D 
insufficiency through vitamin D supplementation.  
The consistent linear association between alkaline phosphatase and mortality as demonstrated 
in this study and several other studies has further emphasized the role of total alkaline 
phosphatase in the management of CKD-MBD. This cheap and readily available test could be 
utilized in resource poor countries as a surrogate marker for monitoring CKD-MBD. 
Although the association between hypercalcaemia and increased mortality has been 
established by previous studies, our study reaffirms the need to pay more attention to 
prevention and correction of hypercalcemia. The majority of our patients are on a calcium-
based phosphate binder which is cheap and effective in controlling serum phosphate. 
However, use of calcium based phosphate binders has been associated with progression of 
vascular calcification (15, 16). Therefore, it is recommended that calcium-based phosphate 
binders should be avoided in patients with adynamic bone disease, hypercalcemia, and 
vascular calcification. On the other hand, cinacalcet which is one of the newer drugs that 
effectively lowers PTH without raising serum calcium levels recently became available in 
South Africa; however, it is quite expensive, thus limiting its use to a few of the patients who 
are able to access it.   
The finding of the existence of racial variations in makers of CKD-MBD in our CKD patients 
further supports the notion that the present guidelines may not to be appropriate for all races 
and thus the need for race-specific target values. 
The observed association between VDR Bb genotype with severity of secondary 
hyperparathyroidism may assist in identifying individuals at an increased risk of developing 
moderate to severe secondary hyperparathyroidism who may require more aggressive 
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management to prevent its development. In addition, genetic factors should be considered 
when designing intervention strategies for secondary hyperparathyroidism. 
7.5 Study limitations 
Our findings should be considered in the context of the following limitations. Firstly, due to 
the cross-sectional study design, we could not determine the longitudinal changes in markers 
of CKD-MBD, as well as seasonal variations in 25 (OH) D levels.  
Secondly, information relating to UVB exposure and dietary phosphate are lacking. Thirdly, 
there is the lack of bone biopsies to definitively describe the pattern of MBD in our patients. 
However, studies have shown a good association between PTH and histological findings. 
Finally, the influence of some wild type genotype (homozygous minor) on the 
calcium/PTH/calcitriol axis could not be adequately determined due to their small numbers. 
Thus, a larger sample will be required to detect their associations with markers of CKD-
MBD.  
However, despite the highlighted limitations, our study has assisted in bridging  the  
knowledge gaps  in the field of CKD-MBD by providing findings that has allowed 
comparisons of data not only for Black Africans with Black Americans, but also between 
whites in Africa and USA/Europe.  
7.6 Conclusions  
Our study showed that the abnormalities of biochemical markers of mineral bone disorder 
were common in our MHD patients and a moderately large proportion of the patients was 
outside the KDIGO recommended target levels. Our study also revealed a significant 
association between high levels of total alkaline phosphatase, hypercalcaemia, and white race 
with death in MHD patients, reaffirming the need to pay more attention to the two modifiable 
risk factors (calcium and TAP) in the management of CKD-MBD. Furthermore, we have also 
demonstrated the existence of racial variations in the markers of CKD- MBD. Finally, we 
have also demonstrated that both moderate and severe secondary hyperparathyroidism were 
predicted by the Bsm I Bb genotype, and the over expression of this genotype in black 
patients may partly explain the ethnic variations in the severity of secondary 
hyperparathyroidism in our CKD population.
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Appendix B : Consent form 
 
UNIVERSITY OF THE WITWATERSRAND  
Participant information and consent form (patient) 
Section A 
STUDY TITLE: Biochemical and Genetic Markers of Mineral Bone Disease in  South 
African patients  with Chronic Kidney Disease. 
INVESTIGATOR: Dr Bala Waziri 
SITE: Charlotte Maxeke Johannesburg Academic Hospital 
TELEPHONE: Cell: 0848329071 
   Land line (Department): 011-488-3672 
Section B 
Introduction 
Good day, my name is Bala Waziri. I am a PhD student doing research at the University of 
the Witwatersrand. Research is an act of investigation or study in order to establish facts and 
reach new conclusions. I am conducting a study on “Biochemical and Genetic Markers of 
Mineral Bone Disease in South Africans with Chronic Kidney Disease”. 
The information that I will collect from this research project will be kept confidential. You 
are hereby invited to take part in the study and your participation in this research is entirely 
voluntary. It is your choice whether to participate or not. Whether you choose to participate 
or not, all the services you receive at this hospital will continue and nothing will change. You 
may change your mind later and stop participating even if you agreed earlier. 
If you have any questions you may ask them now or later, even after the study has started.  
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 It is important that you read and fully understand information on this leaflet as it will help 
you in making the decision. If unable to read or understand English, an interpreter will be 
provided for you. 
Purpose of the study 
I am conducting a study to look at people with chronic kidney disease and why they develop 
bone disease which is one of the complications of chronic kidney disease. The human body 
has two kidneys, which are bean shaped and perform different functions; such as the removal 
of waste products and forming urine. One of the objectives of this study is to determine the 
frequency of bone disease in people with chronic kidney disease. I will also look for 
inheritable factors called genes that regulate the development of bone disease.. 
Genes are basically a collection of information or instructions that form the makeup of a 
human being and decide how he/she behaves.  
I will assess fibroblast growth factor 23 and vitamin D levels and look for the relationship 
between their genes. Fibroblast growth factor 23 and vitamin D are responsible for 
controlling bone disease in people with chronic kidney disease. 
Some people with genetic changes have high risk of developing bone disease compared to 
those with normal genes. One way to demonstrate this relationship is though DNA testing. 
DNA is the chemical compound which genes are made of and is often referred to as the 
building blocks of life. Genetic testing may help in the diagnosis of a disorder.  Genetic 
testing can also be performed for research.  When a gene has changes it is called a mutation. 
 DNA testing is optional and should you agree to participate, a separate DNA consent form 
will be given to read and sign. 
Procedures of the study 
If you agree to participate in the study, your medical records will be reviewed. You will be 
examined by a medical doctor and also interviewed to collect information regarding bone 
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disease. Blood and urine samples will be collected. A total of 10mls (2 teaspoons of blood) 
will be drawn to measure the markers of bone disease and analyze for the genetic changes.  
The blood will be spun very quickly and the serum separated out. The serum which appears 
as a clear fluid will be kept frozen in a small test-tube. Your coded blood samples will be sent 
to Department of Internal Medicine research laboratory for the above mentioned tests. The 
remaining samples will be frozen and stored in a designated freezer for an unlimited period of 
time for future use in research related to diseases. However, if you decide later that you do 
not want the specimens collected from you to be used for future research, please notify the 
principal investigator in writing and the sample will be discarded in an appropriate and timely 
manner. 
Benefits of the study 
The benefits of participating in this study are that we will be able to identify the magnitude of 
bone disease in people with chronic kidney disease. Bone disease is associated with an 
increase in death and this study will assist in picking up bone disease early in people with 
kidney disease. Information that will be obtained from this study will guide our decision in 
prompt management of bone disease which will subsequently reduce the high rate of deaths 
in this group of people.  
Possible risks 
Possible side effects from drawing the blood sample include mild pain, bleeding, and bruising 
at the site of the needle insertion. Qualified personnel will collect the blood samples to 
prevent such complications. 
Financial arrangements 
You will not be paid for participating in the study. However, there will be no costs to you for 
any related study visits and procedures, as any costs incurred will be compensated by 
research funds. 
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Confidentiality 
All information obtained during the course of this study will be kept strictly confidential. 
Your records will be given unique identification numbers and the initial identification details 
won’t be used. All physical records will be kept in a locked locker with access limited to the 
research team. Electronic data will be password protected. 
Source of information 
If you have any questions, queries and clarifications, please contact the following; Dr Bala 
Waziri will be reachable 24 hours every day on the number, 0848329071. 
Additional information can be obtained from the chairperson of Witwatersrand University 
Human Research Ethics Committee, Professor Cleaton Jones on 011-717-2301 
 
Section C 
Informed Consent Form: General (patient) 
I confirm that I have been informed about the study by Dr Bala Waziri. I understand that my 
personal details will be kept strictly confidential and that I may at any stage withdraw my 
consent and participation in the study and continue to receive the appropriate treatment. I 
have also received, read and understood the study as explained in the participant information 
sheet and consent to taking part in this research study. 
 
PARTICIPANT (name)……………………………………………………………….. 
 
Signature or thumb print ……………………………… Date 
……………………………….. 
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Witness (printed 
name)………………………………………………………………………… 
Signature……………………………………………...Date…………………………………
….  
 
I, Dr Bala Waziri confirm that the participant has been fully informed about the nature 
of the above study. 
STUDY INVESTIGATOR  
…………………………………….. Signature……………Date……………….. 
Printed Name  
  
Section D 
Informed consent form: DNA Storage (Patient) 
I hereby confirm that I have been informed about the study by Dr. Bala Waziri about the 
nature, benefits and risks of the genes study.   
I understand that my blood sample will be stored for future testing. 
I understand that my personal details (any identifying data) will be kept strictly confidential. 
 I have had the opportunity to ask questions and I have also received, read and understood the 
study as explained in the participant information sheet and consent to taking part in this 
research study. 
 
PARTICIPANT (name)……………………………………………………………….. 
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Signature or thumb print ……………………………… Date 
……………………………….. 
  
Witness (printed 
name)………………………………………………………………………… 
Signature……………………………………………...Date…………………………………
….  
 
I, Dr Bala Waziri confirm that the participant has been fully informed about the nature 
of the above study. 
STUDY INVESTIGATOR  
 
Name ………………………….. Signature……………Date………………… 
Section E 
Informed consent form: DNA testing (patient) 
I hereby confirm that I have been informed about the study by Dr. Bala Waziri about the 
nature, benefits and risks of the genes study. I understand that my personal details (any 
identifying data) will be kept strictly confidential. I have had the opportunity to ask questions 
and I have also received, read and understood the study as explained in the participant 
information sheet and consent to taking part in this research study. 
 
PARTICIPANT (name)……………………………………………………………….. 
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Signature or thumb print ……………………………… Date 
……………………………….. 
  
Witness (printed 
name)………………………………………………………………………… 
Signature……………………………………………...Date…………………………………
….  
 
I, Dr Bala Waziri confirm that the participant has been fully informed about the nature 
of the above study. 
STUDY INVESTIGATOR  
 
Name ………………………….. Signature……………Date………………… 
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Appendix D:  Data sheet 
Study: Biochemical and Genetic Markers of Mineral Bone Disease in Black South 
Africans with Chronic Kidney Disease. 
 Patients Data Sheet  
Serial Number: ____         Hospital No:  ________   Phone No.____________ 
1.  Age at last Birthday (Years) ____________ 
2.  Sex: Male (   )  Female (   ) 
3.  Ethnicity ______________________ Black (    ) White (   ) 
4.  Marital status: Single (     ) Married ( ) Widow/Widower ( )                              
Separated/Divorced (      ) 
5.  Occupation ___________________ 
6.  History of bone pain in the last one month (a) Yes (b) No 
7.  Presence of Hypertension:  (a) Yes (b) No  
8. Do you have diabetes mellitus? (a) Yes (b) No 
9. Drug history : (a) Calcium supplement ________    і.Duration (months)._____Dose____ 
                            (b) Vitamin D supplement _______і.Duration ( months) ._____Dose____ 
                            (c) Others____________ 
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10. Aetiology of CKD_________________ 
11. Do you smoke cigarette? (a) Yes (b) No  
12. Are you on dialysis (a) Yes (b) No 
13. If answer to 12) is yes what type (a) Peritoneal (a.і) duration (months)____________ 
                                                             (b) Haemodialysis (b. і) duration (months)  _______ 
 Clinical Parameters 
1) Weight (Kg) ______________ 
2) Height (m) _______________ 
3) BMI (Kg/m2) _______________ 
4) Blood Pressure (mmHg)  _____________ 
Investigations.  
Parathyroid hormone (PTH)______________  
Fibroblast growth factor 23 (FGF23)  ______________     
Albumin  ______________        Calcium  ______________   
 Phosphate   ______________     Ca× PO4 ______________ 
Total alkaline phosphate (TAP)  _____________  
25-OH vitaminD______________ Serum Creatinine (µmol/L)  ______________    
Urea (mmol/L) ______________          Total Cholesterol______________   
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LDL    _____________ HDL______________ TG ______________         
 Estimated GFR:     _____________ 
Genetic analysis 
VDR genotypes:  
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